Silicone based membranes for use in implantable glucose sensors
First Claim
1. A membrane layer for use in an analyte sensor, comprising a blend of a silicone polymer with a co-polymer comprising a polymeric hydrophobic domain and a polymeric hydrophilic domain, wherein the membrane is adapted to permit diffusion of both the analyte and oxygen therethrough.
1 Assignment
0 Petitions

Accused Products

Abstract
Membrane systems incorporating silicone polymers are described for use in implantable analyte sensors. Some layers of the membrane system may comprise a blend of a silicone polymer with a hydrophilic polymer, for example, a triblock poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) polymer. Such polymeric blends provide for both high oxygen solubility and aqueous analyte solubility.
371 Citations
Analyte monitoring device and methods of use | ||
Patent #
US 7,885,699 B2
Filed 08/06/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 7,885,697 B2
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Low oxygen in vivo analyte sensor | ||
Patent #
US 7,899,511 B2
Filed 01/17/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
DUAL ELECTRODE SYSTEM FOR A CONTINUOUS ANALYTE SENSOR | ||
Patent #
US 20110046467A1
Filed 10/29/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 7,905,833 B2
Filed 06/21/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 7,896,809 B2
Filed 11/03/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Low oxygen in vivo analyte sensor | ||
Patent #
US 7,901,354 B2
Filed 05/01/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 7,869,853 B1
Filed 08/06/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 7,946,984 B2
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 7,949,381 B2
Filed 04/11/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring system and method | ||
Patent #
US 7,920,907 B2
Filed 06/07/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 7,970,448 B2
Filed 04/19/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Blood glucose tracking apparatus | ||
Patent #
US 7,976,778 B2
Filed 06/22/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,000,901 B2
Filed 08/09/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 7,974,672 B2
Filed 04/19/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
WATER FLUX POLYMER MEMBRANES | ||
Patent #
US 20110207841A1
Filed 10/09/2009
|
Current Assignee
Arkema Incorporated
|
Original Assignee
Arkema Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 7,860,544 B2
Filed 03/07/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 7,792,562 B2
Filed 12/22/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Low oxygen in vivo analyte sensor | ||
Patent #
US 7,771,352 B2
Filed 05/01/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 7,761,130 B2
Filed 03/27/2007
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
IMPLANTABLE BIOSENSOR AND SENSOR ARRANGEMENT | ||
Patent #
US 20100056888A1
Filed 08/13/2009
|
Current Assignee
Biotronik SE Company KG
|
Original Assignee
Biotronik VI Patent AG
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 7,831,287 B2
Filed 04/28/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 7,835,777 B2
Filed 12/22/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 7,654,956 B2
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous medical device with variable stiffness | ||
Patent #
US 7,783,333 B2
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 7,828,728 B2
Filed 02/14/2007
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 7,857,760 B2
Filed 02/22/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Silicone based membranes for use in implantable glucose sensors | ||
Patent #
US 7,613,491 B2
Filed 04/14/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 7,640,048 B2
Filed 02/22/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensors and methods for making and using them | ||
Patent #
US 20080026473A1
Filed 07/25/2006
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
Enhanced Oxygen Cell Culture Platforms | ||
Patent #
US 20080009027A1
Filed 07/09/2007
|
Current Assignee
University of Miami
|
Original Assignee
University of Miami
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 7,379,765 B2
Filed 07/21/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 20050054909A1
Filed 07/21/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Silicone based membranes for use in implantable glucose sensors | ||
Patent #
US 8,064,977 B2
Filed 07/29/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
RF tag on test strips, test strip vials and boxes | ||
Patent #
US 8,115,635 B2
Filed 11/24/2009
|
Current Assignee
Therasense Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor | ||
Patent #
US 8,133,178 B2
Filed 02/22/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,160,669 B2
Filed 04/11/2007
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Calibration techniques for a continuous analyte sensor | ||
Patent #
US 8,160,671 B2
Filed 09/01/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,162,829 B2
Filed 03/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,175,673 B2
Filed 11/09/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,177,716 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Electrode systems for electrochemical sensors | ||
Patent #
US RE43,399 E1
Filed 06/13/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,224,413 B2
Filed 10/10/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
RF tag on test strips, test strip vials and boxes | ||
Patent #
US 8,223,021 B2
Filed 11/24/2009
|
Current Assignee
Therasense Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,226,558 B2
Filed 09/27/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,226,557 B2
Filed 12/28/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,226,555 B2
Filed 03/18/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,229,534 B2
Filed 10/26/2007
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,231,532 B2
Filed 04/30/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Blood glucose tracking apparatus and methods | ||
Patent #
US 8,236,242 B2
Filed 02/12/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,235,896 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Calibration techniques for a continuous analyte sensor | ||
Patent #
US 8,249,684 B2
Filed 09/01/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 8,255,032 B2
Filed 01/15/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 8,255,030 B2
Filed 04/25/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,255,031 B2
Filed 03/17/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 8,255,033 B2
Filed 04/25/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,260,392 B2
Filed 06/09/2008
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,265,726 B2
Filed 11/09/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Blood glucose tracking apparatus and methods | ||
Patent #
US 8,268,243 B2
Filed 12/28/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,273,022 B2
Filed 02/13/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,275,439 B2
Filed 11/09/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,275,437 B2
Filed 03/23/2007
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Implantable analyte sensor | ||
Patent #
US 8,277,713 B2
Filed 05/03/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,280,475 B2
Filed 02/23/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,287,454 B2
Filed 09/27/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor | ||
Patent #
US 8,287,453 B2
Filed 11/07/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,306,598 B2
Filed 11/09/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Implantable biosensor and sensor arrangement | ||
Patent #
US 8,323,193 B2
Filed 08/13/2009
|
Current Assignee
Biotronik SE Company KG
|
Original Assignee
Biotronik VI Patent AG
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,346,336 B2
Filed 03/18/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,346,337 B2
Filed 06/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,353,829 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
THREE DIMENSIONAL MICROFLUIDIC MULTIPLEXED DIAGNOSTIC SYSTEM | ||
Patent #
US 20130018243A1
Filed 07/13/2012
|
Current Assignee
Leidos Innovations Technology Inc.
|
Original Assignee
Lockheed Martin Corporation
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,357,091 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
RF tag on test strips, test strip vials and boxes | ||
Patent #
US 8,358,210 B2
Filed 11/24/2009
|
Current Assignee
Therasense Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise | ||
Patent #
US 8,364,229 B2
Filed 05/18/2007
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,366,614 B2
Filed 03/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,372,005 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,380,273 B2
Filed 04/11/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Calibration techniques for a continuous analyte sensor | ||
Patent #
US 8,386,004 B2
Filed 09/07/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
RF tag on test strips, test strip vials and boxes | ||
Patent #
US 8,390,455 B2
Filed 11/24/2009
|
Current Assignee
Therasense Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,391,945 B2
Filed 03/17/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,394,021 B2
Filed 10/01/2007
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 8,396,528 B2
Filed 03/25/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,409,131 B2
Filed 03/07/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Systems and methods for processing sensor data | ||
Patent #
US 8,417,312 B2
Filed 10/24/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 8,423,114 B2
Filed 10/01/2007
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Calibration techniques for a continuous analyte sensor | ||
Patent #
US 8,428,678 B2
Filed 05/16/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,452,368 B2
Filed 01/14/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,457,708 B2
Filed 12/05/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,465,425 B2
Filed 06/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,473,021 B2
Filed 07/31/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,475,373 B2
Filed 07/17/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,480,580 B2
Filed 04/19/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,483,791 B2
Filed 04/11/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 8,483,793 B2
Filed 10/29/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Sensor head for use with implantable devices | ||
Patent #
US 8,509,871 B2
Filed 10/28/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,515,519 B2
Filed 02/26/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 8,527,025 B1
Filed 11/22/1999
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Glucose measurement device and methods using RFID | ||
Patent #
US 8,542,122 B2
Filed 01/17/2013
|
Current Assignee
Therasense Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Silicone based membranes for use in implantable glucose sensors | ||
Patent #
US 8,543,184 B2
Filed 10/20/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Enhanced oxygen cell culture platforms | ||
Patent #
US 8,551,770 B2
Filed 07/09/2007
|
Current Assignee
University of Miami
|
Original Assignee
University of Miami
|
Particle-containing membrane and particulate electrode for analyte sensors | ||
Patent #
US 8,560,039 B2
Filed 09/17/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,565,848 B2
Filed 05/07/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 8,583,204 B2
Filed 03/05/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,597,189 B2
Filed 03/03/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,612,159 B2
Filed 02/16/2004
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor | ||
Patent #
US 8,615,282 B2
Filed 02/22/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,617,071 B2
Filed 06/21/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,622,905 B2
Filed 12/11/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,622,906 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US RE44,695 E1
Filed 05/01/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,641,619 B2
Filed 12/21/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,649,841 B2
Filed 04/03/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,652,043 B2
Filed 07/20/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,660,627 B2
Filed 03/17/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,663,109 B2
Filed 03/29/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,666,469 B2
Filed 11/16/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,668,645 B2
Filed 01/03/2003
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,670,815 B2
Filed 04/30/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,672,844 B2
Filed 02/27/2004
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,676,287 B2
Filed 12/11/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 8,676,288 B2
Filed 06/22/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 8,682,408 B2
Filed 03/05/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,688,188 B2
Filed 06/30/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,690,775 B2
Filed 04/11/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
ENHANCED OXYGEN CELL CULTURE PLATFORMS | ||
Patent #
US 20140099717A1
Filed 10/07/2013
|
Current Assignee
University of Miami
|
Original Assignee
University of Miami
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,700,117 B2
Filed 12/08/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,721,545 B2
Filed 03/22/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,734,348 B2
Filed 03/17/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,734,346 B2
Filed 04/30/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,738,109 B2
Filed 03/03/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Cellulosic-based resistance domain for an analyte sensor | ||
Patent #
US 8,744,546 B2
Filed 04/28/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,744,545 B2
Filed 03/03/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor | ||
Patent #
US 8,750,955 B2
Filed 11/02/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Blood glucose tracking apparatus | ||
Patent #
US 8,765,059 B2
Filed 10/27/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,774,887 B2
Filed 03/24/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
System and methods for processing analyte sensor data | ||
Patent #
US 8,788,006 B2
Filed 12/11/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,788,007 B2
Filed 03/08/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,792,953 B2
Filed 03/19/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,801,611 B2
Filed 03/22/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous medical device with variable stiffness | ||
Patent #
US 8,812,072 B2
Filed 04/17/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensors and methods of manufacturing same | ||
Patent #
US 8,828,201 B2
Filed 07/01/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,840,553 B2
Filed 02/26/2009
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Techniques to improve polyurethane membranes for implantable glucose sensors | ||
Patent #
US 8,865,249 B2
Filed 09/28/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,880,137 B2
Filed 04/18/2003
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensor | ||
Patent #
US 8,886,272 B2
Filed 02/22/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 8,909,314 B2
Filed 07/20/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 8,911,369 B2
Filed 12/15/2008
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,915,849 B2
Filed 02/03/2009
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,915,850 B2
Filed 03/28/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,920,319 B2
Filed 12/28/2012
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 8,929,968 B2
Filed 07/19/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 8,954,128 B2
Filed 10/18/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 8,974,386 B2
Filed 11/01/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 8,986,209 B2
Filed 07/13/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,011,332 B2
Filed 10/30/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,011,331 B2
Filed 12/29/2004
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,014,773 B2
Filed 03/07/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,042,953 B2
Filed 03/02/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 9,044,199 B2
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 9,055,901 B2
Filed 09/14/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,066,695 B2
Filed 04/12/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,066,697 B2
Filed 10/27/2011
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,066,694 B2
Filed 04/03/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,072,477 B2
Filed 06/21/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 9,078,626 B2
Filed 03/31/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,078,607 B2
Filed 06/17/2013
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte sensors and methods of manufacturing same | ||
Patent #
US 9,131,885 B2
Filed 07/01/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Low oxygen in vivo analyte sensor | ||
Patent #
US 9,155,496 B2
Filed 02/18/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 9,173,607 B2
Filed 01/30/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Enhanced oxygen cell culture platforms | ||
Patent #
US 9,175,254 B2
Filed 10/07/2013
|
Current Assignee
University of Miami
|
Original Assignee
University of Miami
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 9,173,606 B2
Filed 01/30/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Techniques to improve polyurethane membranes for implantable glucose sensors | ||
Patent #
US 9,179,869 B2
Filed 09/10/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensors and methods of manufacturing same | ||
Patent #
US 9,237,864 B2
Filed 07/01/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensors and methods for making and using them | ||
Patent #
US 9,237,865 B2
Filed 07/25/2006
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
Analyte sensor | ||
Patent #
US 9,247,900 B2
Filed 06/04/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Biosensor membrane composition, biosensor, and methods for making same | ||
Patent #
US 9,322,103 B2
Filed 08/05/2011
|
Current Assignee
Microchips Biotech Inc.
|
Original Assignee
Microchips Biotech Inc.
|
Analyte sensor | ||
Patent #
US 9,320,466 B2
Filed 10/18/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,326,716 B2
Filed 12/05/2014
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Sensor head for use with implantable devices | ||
Patent #
US 9,328,371 B2
Filed 07/16/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,326,714 B2
Filed 06/29/2010
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 9,339,223 B2
Filed 12/30/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Particle-containing membrane and particulate electrode for analyte sensors | ||
Patent #
US 9,339,222 B2
Filed 05/31/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor with increased reference capacity | ||
Patent #
US 9,351,677 B2
Filed 03/04/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 9,414,777 B2
Filed 03/10/2005
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 9,439,589 B2
Filed 11/25/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 9,451,910 B2
Filed 08/27/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 9,451,908 B2
Filed 12/19/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Blood glucose tracking apparatus and methods | ||
Patent #
US 9,477,811 B2
Filed 06/23/2005
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,498,159 B2
Filed 10/30/2007
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 9,504,413 B2
Filed 04/15/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor with increased reference capacity | ||
Patent #
US 9,517,025 B2
Filed 05/12/2016
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Silicone based membranes for use in implantable glucose sensors | ||
Patent #
US 9,549,693 B2
Filed 07/25/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 9,549,699 B2
Filed 10/17/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 9,566,026 B2
Filed 10/17/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 9,572,523 B2
Filed 09/22/2015
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 9,579,053 B2
Filed 03/26/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 9,597,027 B2
Filed 10/30/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 9,610,034 B2
Filed 11/09/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 9,610,031 B2
Filed 04/13/2011
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 9,668,677 B2
Filed 10/26/2015
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 9,668,682 B2
Filed 12/18/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 9,693,721 B2
Filed 06/17/2015
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Water flux polymer membranes | ||
Patent #
US 9,707,524 B2
Filed 10/09/2009
|
Current Assignee
Arkema Incorporated
|
Original Assignee
Arkema Incorporated
|
Systems and methods for processing sensor data | ||
Patent #
US 9,717,449 B2
Filed 01/15/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 9,724,028 B2
Filed 11/24/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Low oxygen in vivo analyte sensor | ||
Patent #
US 9,757,061 B2
Filed 09/01/2015
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensors and methods of manufacturing same | ||
Patent #
US 9,763,608 B2
Filed 12/04/2015
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise | ||
Patent #
US 9,763,609 B2
Filed 01/02/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 9,775,543 B2
Filed 12/30/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Techniques to improve polyurethane membranes for implantable glucose sensors | ||
Patent #
US 9,801,574 B2
Filed 10/05/2015
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Sensor head for use with implantable devices | ||
Patent #
US 9,804,114 B2
Filed 03/02/2016
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 9,814,414 B2
Filed 03/30/2010
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 9,833,176 B2
Filed 07/12/2012
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 9,907,497 B2
Filed 10/18/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 9,931,067 B2
Filed 09/13/2016
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 9,986,942 B2
Filed 08/10/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 9,993,186 B2
Filed 02/09/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 10,022,078 B2
Filed 05/23/2006
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Particle-containing membrane and particulate electrode for analyte sensors | ||
Patent #
US 10,028,683 B2
Filed 10/07/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Particle-containing membrane and particulate electrode for analyte sensors | ||
Patent #
US 10,028,684 B2
Filed 09/21/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Silicone based membranes for use in implantable glucose sensors | ||
Patent #
US 10,052,051 B2
Filed 10/27/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Three dimensional microfluidic multiplexed diagnostic system | ||
Patent #
US 10,080,526 B2
Filed 07/13/2012
|
Current Assignee
Leidos Innovations Technology Inc.
|
Original Assignee
Leidos Innovations Technology Inc.
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 10,136,844 B2
Filed 11/18/2016
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Polymer membranes for continuous analyte sensors | ||
Patent #
US 10,143,410 B2
Filed 06/01/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Techniques to improve polyurethane membranes for implantable glucose sensors | ||
Patent #
US 10,154,807 B2
Filed 09/27/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for processing sensor data | ||
Patent #
US 10,182,751 B2
Filed 06/26/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Calibration techniques for a continuous analyte sensor | ||
Patent #
US 10,188,333 B2
Filed 08/17/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 10,201,301 B2
Filed 04/18/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 10,231,654 B2
Filed 06/23/2015
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Low oxygen in vivo analyte sensor | ||
Patent #
US 10,265,000 B2
Filed 08/03/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Implantable biocompatible SiC sensors | ||
Patent #
US 10,278,629 B2
Filed 03/12/2013
|
Current Assignee
University of South Florida
|
Original Assignee
Mississippi State University, University of South Florida
|
Dual electrode system for a continuous analyte sensor | ||
Patent #
US 10,299,712 B2
Filed 09/05/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Cellulosic-based resistance domain for an analyte sensor | ||
Patent #
US 10,300,507 B2
Filed 02/14/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 10,314,525 B2
Filed 01/06/2015
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Film for biosensors and preparation method | ||
Patent #
US 10,321,864 B2
Filed 04/04/2014
|
Current Assignee
Medtrum Technologies Inc.
|
Original Assignee
Medtrum Technologies Inc.
|
Analyte sensor | ||
Patent #
US 10,349,873 B2
Filed 04/27/2016
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise | ||
Patent #
US 10,376,143 B2
Filed 12/31/2013
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 10,420,494 B2
Filed 01/23/2018
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor with increased reference capacity | ||
Patent #
US 10,470,691 B2
Filed 12/06/2016
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte monitoring device and methods of use | ||
Patent #
US 10,478,108 B2
Filed 02/05/2016
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Abbott Diabetes Care Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 10,524,703 B2
Filed 01/24/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for display device and sensor electronics unit communication | ||
Patent #
US 10,561,349 B2
Filed 03/28/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Particle-containing membrane and particulate electrode for analyte sensors | ||
Patent #
US 10,561,352 B2
Filed 07/03/2018
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for display device and sensor electronics unit communication | ||
Patent #
US 10,568,552 B2
Filed 03/28/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 10,602,968 B2
Filed 09/10/2014
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 10,610,103 B2
Filed 08/16/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,610,137 B2
Filed 06/28/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 10,610,102 B2
Filed 07/03/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,610,136 B2
Filed 06/28/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 10,610,140 B2
Filed 05/11/2018
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,610,135 B2
Filed 06/28/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,617,336 B2
Filed 06/28/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 10,624,539 B2
Filed 07/03/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,709,364 B2
Filed 11/21/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Transcutaneous analyte sensor | ||
Patent #
US 10,709,332 B2
Filed 08/16/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 10,709,362 B2
Filed 11/21/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 10,709,363 B2
Filed 11/21/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,716,498 B2
Filed 11/21/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 10,722,152 B2
Filed 11/05/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,743,801 B2
Filed 11/21/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise | ||
Patent #
US 10,791,928 B2
Filed 02/20/2020
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 10,799,158 B2
Filed 11/21/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for display device and sensor electronics unit communication | ||
Patent #
US 10,799,157 B2
Filed 08/29/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 10,799,159 B2
Filed 02/13/2020
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 10,813,577 B2
Filed 02/13/2020
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte sensor | ||
Patent #
US 10,813,576 B2
Filed 11/21/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Remote monitoring of analyte measurements | ||
Patent #
US 10,856,736 B2
Filed 03/26/2020
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
System and methods for processing analyte sensor data for sensor calibration | ||
Patent #
US 10,856,787 B2
Filed 07/31/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Remote monitoring of analyte measurements | ||
Patent #
US 10,860,687 B2
Filed 06/23/2017
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Remote monitoring of analyte measurements | ||
Patent #
US 10,869,599 B2
Filed 03/26/2020
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Systems and methods for display device and sensor electronics unit communication | ||
Patent #
US 10,881,335 B2
Filed 08/29/2019
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Current collection through thermally sprayed tabs at the ends of a spirally wound electrochemical cell | ||
Patent #
US 6,187,062 B1
Filed 06/16/1998
|
Current Assignee
Saft Finance Sarl
|
Original Assignee
Alcatel-Lucent SA
|
SYSTEMS AND METHODS FOR MANUFACTURE OF AN ANALYTE-MEASURING DEVICE INCLUDING A MEMBRANE SYSTEM | ||
Patent #
US 20060015020A1
Filed 07/06/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Biointerface membranes incorporating bioactive agents | ||
Patent #
US 20050031689A1
Filed 05/10/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Analyte measuring device | ||
Patent #
US 20050033132A1
Filed 05/14/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Rolled electrode array and its method for manufacture | ||
Patent #
US 20050051427A1
Filed 07/21/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Oxygen enhancing membrane systems for implantable devices | ||
Patent #
US 20050054909A1
Filed 07/21/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Increasing bias for oxygen production in an electrode system | ||
Patent #
US 20050056552A1
Filed 07/21/2004
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 20040011671A1
Filed 07/27/2001
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Device and method for determining analyte levels | ||
Patent #
US 20040045879A1
Filed 09/09/2003
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Membrane for use with implantable devices | ||
Patent #
US 6,702,857 B2
Filed 07/27/2001
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Membrane and electrode structure for implantable sensor | ||
Patent #
US 6,721,587 B2
Filed 02/15/2002
|
Current Assignee
Regents of the University of California
|
Original Assignee
Regents of the University of California
|
Membrane for use with implantable devices | ||
Patent #
US 20030023317A1
Filed 07/27/2001
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Rolled electroactive polymers | ||
Patent #
US 20030006669A1
Filed 05/21/2002
|
Current Assignee
SRI International Inc.
|
Original Assignee
SRI International Inc.
|
Porous three dimensional structure | ||
Patent #
US 6,520,997 B1
Filed 12/07/2000
|
Current Assignee
Baxter International Inc.
|
Original Assignee
Baxter International Inc.
|
Medical implant having bioabsorbable textured surface | ||
Patent #
US 20030036803A1
Filed 08/14/2001
|
Current Assignee
Whd Electronische Prueftechnik
|
Original Assignee
Jim J. Mcghan
|
Sensor head for use with implantable devices | ||
Patent #
US 20030032874A1
Filed 07/27/2001
|
Current Assignee
DexCom Incorporated
|
Original Assignee
DexCom Incorporated
|
Subcutaneous glucose electrode | ||
Patent #
US 6,514,718 B2
Filed 11/29/2001
|
Current Assignee
Therasense Incorporated
|
Original Assignee
Therasense Incorporated
|
Multi-component polymeric networks containing poly(ethylene glycol) | ||
Patent #
US 6,528,584 B2
Filed 04/12/2001
|
Current Assignee
University of Akron
|
Original Assignee
University of Akron
|
Use of glucomannan hydrocolloid as filler material in prostheses | ||
Patent #
US 6,537,318 B1
Filed 04/06/1998
|
Current Assignee
KONJAC TECHNOLOGIES L.L.C.
|
Original Assignee
KONJAC TECHNOLOGIES LLC
|
Method for monitoring patient using acoustic sensor | ||
Patent #
US 6,527,729 B1
Filed 10/11/2000
|
Current Assignee
Pacesetter Incorporated
|
Original Assignee
Pacesetter Incorporated
|
Biocompatible medical articles and process for their production | ||
Patent #
US 20030059631A1
Filed 09/23/2002
|
Current Assignee
Bayer Materialscience AG
|
Original Assignee
Phylogenetix Laboratories Inc.
|
Implantable enzyme-based monitoring system having improved longevity due to improved exterior surfaces | ||
Patent #
US 20030065254A1
Filed 10/31/2002
|
Current Assignee
Alfred E. Mann Foundation For Scientific Research
|
Original Assignee
Alfred E. Mann Foundation For Scientific Research
|
Implantable sensor electrodes and electronic circuitry | ||
Patent #
US 20030076082A1
Filed 12/28/2001
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
Microstructured bilateral sensor | ||
Patent #
US 6,551,496 B1
Filed 03/06/2001
|
Current Assignee
YSI Incorporated
|
Original Assignee
YSI Incorporated
|
Glucose sensor | ||
Patent #
US 6,546,268 B1
Filed 06/02/2000
|
Current Assignee
Ball Semiconductor Inc.
|
Original Assignee
Ball Semiconductor Inc.
|
Nanoporous silicone resins having low dielectric constants | ||
Patent #
US 6,541,107 B1
Filed 10/25/1999
|
Current Assignee
Dow Inc.
|
Original Assignee
Dow Inc.
|
Glucose sensor package system | ||
Patent #
US 20030078481A1
Filed 11/26/2002
|
Current Assignee
Minimed Inc.
|
Original Assignee
Minimed Inc.
|
Sensor membrane, a method for the preparation thereof, a sensor and a layered membrane structure for such sensor | ||
Patent #
US 20030070548A1
Filed 11/21/2002
|
Current Assignee
Radiometer Medical ApS
|
Original Assignee
Radiometer Medical ApS
|
Polar solvent compatible polyethersiloxane elastomers | ||
Patent #
US 6,545,085 B2
Filed 10/05/2001
|
Current Assignee
Citibank South Dakota NA
|
Original Assignee
General Electric Company
|
Method of making an electrochemical cell by the application of polysiloxane onto at least one of the cell components | ||
Patent #
US 6,547,839 B2
Filed 01/23/2001
|
Current Assignee
SKC Company Limited
|
Original Assignee
SKC Company Limited
|
Method and system for non-vascular sensor implantation | ||
Patent #
US 20030078560A1
Filed 12/27/2001
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Medtronic Minimed Incorporated
|
Tissue engineering composite | ||
Patent #
US 20020022883A1
Filed 06/12/2001
|
Current Assignee
Clemson University
|
Original Assignee
Clemson University
|
Subcutaneous glucose electrode | ||
Patent #
US 20020042090A1
Filed 11/29/2001
|
Current Assignee
Therasense Incorporated
|
Original Assignee
Therasense Incorporated
|
RETRIEVABLE BIOARTIFICIAL IMPLANTS HAVING DIMENSIONS ALLOWING RAPID DIFFUSION OF OXYGEN AND RAPID BIOLOGICAL RESPONSE TO PHYSIOLOGICAL CHANGE, PROCESSES FOR THEIR MANUFACTURE, AND METHODS FOR THEIR USE | ||
Patent #
US 6,372,244 B1
Filed 08/25/2000
|
Current Assignee
Islet Sheet Medical LLC
|
Original Assignee
ISLET SHEET MEDICAL INC.
|
Organopolysiloxane gels for use in cosmetics | ||
Patent #
US 6,365,670 B1
Filed 03/10/2000
|
Current Assignee
Wacker Chemical Corporation
|
Original Assignee
Wacker Silicones Corporation
|
Analyte monitoring device and methods of use | ||
Patent #
US 6,175,752 B1
Filed 04/30/1998
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Therasense Incorporated
|
Implantable medical sensor system | ||
Patent #
US 6,201,980 B1
Filed 10/05/1998
|
Current Assignee
Lawrence Livermore National Security LLC
|
Original Assignee
Regents of the University of California
|
Modified polyurethane membrane sensors and analytical methods | ||
Patent #
US 6,200,772 B1
Filed 05/10/2000
|
Current Assignee
Sensalyse Holdings Limited
|
Original Assignee
Sensalyse Holdings Limited
|
System of implantable devices for monitoring and/or affecting body parameters | ||
Patent #
US 6,208,894 B1
Filed 03/25/1998
|
Current Assignee
Boston Scientific Neuromodulation Corporation
|
Original Assignee
Alfred E. Mann Foundation For Scientific Research
|
Implantable monitor | ||
Patent #
US 6,230,059 B1
Filed 03/17/1999
|
Current Assignee
Medtronic Incorporated
|
Original Assignee
Medtronic Incorporated
|
Biocompatible devices with foam scaffolds | ||
Patent #
US 6,231,879 B1
Filed 02/09/1999
|
Current Assignee
Neurotech USA Inc.
|
Original Assignee
Neurotech S.A.
|
Multilevel ERI for implantable medical devices | ||
Patent #
US 6,016,448 A
Filed 10/27/1998
|
Current Assignee
Medtronic Incorporated
|
Original Assignee
Medtronic Incorporated
|
Coating composition and method for producing precoated steel sheets | ||
Patent #
US 6,018,013 A
Filed 08/24/1998
|
Current Assignee
JFE Steel Corporation
|
Original Assignee
NSK Corporation
|
Detection of biological molecules using chemical amplification and optical sensors | ||
Patent #
US 6,011,984 A
Filed 11/21/1996
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Minimed Inc.
|
Slotted insulator for unsealed electrode edges in electrochemical cells | ||
Patent #
US 6,013,113 A
Filed 03/06/1998
|
Current Assignee
Greatbatch Limited
|
Original Assignee
Wilson Greatbatch Technologies Inc.
|
Implantable sensor and system for in vivo measurement and control of fluid constituent levels | ||
Patent #
US 6,049,727 A
Filed 04/03/1998
|
Current Assignee
Animas Corporation
|
Original Assignee
Animas Corporation
|
Sensors for sugars and other metal binding analytes | ||
Patent #
US 6,063,637 A
Filed 07/07/1997
|
Current Assignee
California Institute of Technology
|
Original Assignee
California Institute of Technology
|
Implantable medical device microstrip telemetry antenna | ||
Patent #
US 5,861,019 A
Filed 07/25/1997
|
Current Assignee
Medtronic Incorporated
|
Original Assignee
Medtronic Incorporated
|
Attachment apparatus for an implantable medical device employing ultrasonic energy | ||
Patent #
US 5,871,514 A
Filed 08/01/1997
|
Current Assignee
Medtronic Incorporated
|
Original Assignee
Medtronic Incorporated
|
Polyurethane/polyurea compositions containing silicone for biosensor membranes | ||
Patent #
US 5,882,494 A
Filed 08/28/1995
|
Current Assignee
Minimed Inc.
|
Original Assignee
Minimed Inc.
|
Attachment apparatus and method for an implantable medical device employing ultrasonic energy | ||
Patent #
US 5,897,578 A
Filed 08/27/1998
|
Current Assignee
Medtronic Incorporated
|
Original Assignee
Medtronic Incorporated
|
System and method for deriving relative physiologic signals | ||
Patent #
US 5,904,708 A
Filed 03/19/1998
|
Current Assignee
Medtronic Incorporated
|
Original Assignee
Medtronic Incorporated
|
Device for monitoring changes in analyte concentration | ||
Patent #
US 5,711,861 A
Filed 11/22/1995
|
Current Assignee
LEGACY GOOD SAMARITAN HOSPITAL AND MEDICAL CENTER
|
Original Assignee
Ward W. Kenneth, Eric S. Wilgus
|
Sensor device covered with foam membrane | ||
Patent #
US 5,706,807 A
Filed 10/11/1996
|
Current Assignee
Applied Medical Research
|
Original Assignee
Applied Medical Research
|
Tissue implant systems | ||
Patent #
US 5,713,888 A
Filed 06/05/1995
|
Current Assignee
Baxalta Incorporated, Baxalta GmbH
|
Original Assignee
Baxter International Inc.
|
Ported tissue implant systems and methods of using same | ||
Patent #
US 5,733,336 A
Filed 03/30/1995
|
Current Assignee
Baxter International Inc.
|
Original Assignee
Baxter International Inc.
|
Close vascularization implant material | ||
Patent #
US 5,741,330 A
Filed 06/07/1995
|
Current Assignee
Baxalta Incorporated, Baxalta GmbH
|
Original Assignee
Baxter International Inc.
|
Systems for premeating molecules of predetermined molecular weight range | ||
Patent #
US 5,756,632 A
Filed 06/02/1995
|
Current Assignee
Polymer Technology Group Inc.
|
Original Assignee
Polymer Technology Group Inc.
|
Subcutaneous glucose electrode | ||
Patent #
US 5,593,852 A
Filed 09/01/1994
|
Current Assignee
Abbott Diabetes Care Incorporated
|
Original Assignee
Adam Heller, Michael V. Pishko
|
Tissue implant systems and methods for sustaining viable high cell densities within a host | ||
Patent #
US 5,593,440 A
Filed 05/23/1994
|
Current Assignee
Baxter International Inc.
|
Original Assignee
Baxter International Inc.
|
Microbiosensor used in-situ | ||
Patent #
US 5,611,900 A
Filed 07/20/1995
|
Current Assignee
Michigan State University
|
Original Assignee
Michigan State University
|
Electrochemical sensor | ||
Patent #
US 5,628,890 A
Filed 09/27/1995
|
Current Assignee
Medisense Incorporated
|
Original Assignee
Medisense Incorporated
|
Biosensor and method of quantitative analysis using the same | ||
Patent #
US 5,496,453 A
Filed 10/12/1994
|
Current Assignee
Kyoto Daiichi Kagaku Company Limited
|
Original Assignee
Kyoto Daiichi Kagaku Company Limited
|
Biocompatible microcapsules | ||
Patent #
US 5,380,536 A
Filed 08/05/1991
|
Current Assignee
Board of Regents of the University of Texas System
|
Original Assignee
Board of Regents of the University of Texas System
|
Biosensor with a data memory | ||
Patent #
US 5,384,028 A
Filed 08/27/1993
|
Current Assignee
NEC Corporation
|
Original Assignee
NEC Corporation
|
Method of fabricating thin film sensors | ||
Patent #
US 5,391,250 A
Filed 03/15/1994
|
Current Assignee
Medtronic Minimed Incorporated
|
Original Assignee
Minimed Inc.
|
Enhancing the hydrophilicity of silicone polymers | ||
Patent #
US 5,397,848 A
Filed 05/21/1993
|
Current Assignee
Abbott Medical Optics Incorporated
|
Original Assignee
Allergan Inc. Canada
|
Self-supporting woven vascular graft | ||
Patent #
US 5,282,848 A
Filed 04/19/1993
|
Current Assignee
Maquet Cardiovascular LLC
|
Original Assignee
Meadox Medicals Inc.
|
Tissue inplant systems and methods for sustaining viable high cell densities within a host | ||
Patent #
US 5,314,471 A
Filed 04/01/1992
|
Current Assignee
Baxter International Inc.
|
Original Assignee
Baxter International Inc.
|
System for monitoring and controlling blood glucose | ||
Patent #
US 5,190,041 A
Filed 12/27/1991
|
Current Assignee
CB-CARMEL BIOTECHNOLOGY LTD.
|
Original Assignee
CB-CARMEL BIOTECHNOLOGY LTD.
|
System for monitoring and controlling blood glucose | ||
Patent #
US 5,101,814 A
Filed 08/11/1989
|
Current Assignee
CB-CARMEL BIOTECHNOLOGY LTD.
|
Original Assignee
Yoram Palti
|
Device for the determination of incisional wound healing ability | ||
Patent #
US 5,113,871 A
Filed 03/15/1990
|
Current Assignee
Jouko Viljanto, Timo Hurula, Rainer Govenius, Kurt Lonnqvist
|
Original Assignee
Jouko Viljanto, Timo Hurula, Rainer Govenius, Kurt Lonnqvist
|
Fitting for fastening the rail member of a drawer | ||
Patent #
US 4,984,929 A
Filed 05/16/1989
|
Current Assignee
Julius BLUM GmbH
|
Original Assignee
Julius BLUM GmbH
|
Three-parameter optical fiber sensor and system | ||
Patent #
US 4,986,671 A
Filed 04/12/1989
|
Current Assignee
Luxtron Corp.
|
Original Assignee
Luxtron Corp.
|
Biological fluid measuring device | ||
Patent #
US 4,994,167 A
Filed 07/07/1988
|
Current Assignee
DexCom Incorporated
|
Original Assignee
Markwell Medical Institute Inc.
|
Biological implant with textured surface | ||
Patent #
US 5,002,572 A
Filed 11/22/1988
|
Current Assignee
Baxter International Inc.
|
Original Assignee
George J. Picha Dr.
|
Open-cell, silicone-elastomer medical implant | ||
Patent #
US 5,007,929 A
Filed 07/27/1990
|
Current Assignee
Allergan Inc. Canada
|
Original Assignee
MEDICAL PRODUCTS DEVELOPMENT INC.
|
Two-dimensional diffusion glucose substrate sensing electrode | ||
Patent #
US 4,890,620 A
Filed 02/17/1988
|
Current Assignee
Regents of the University of California
|
Original Assignee
Regents of the University of California
|
Cardiac assist pump with steady rate supply of fluid lubricant | ||
Patent #
US 4,927,407 A
Filed 06/19/1989
|
Current Assignee
Regents of The University of Minnesota
|
Original Assignee
Regents of The University of Minnesota
|
Block-graft copolymer | ||
Patent #
US 4,803,243 A
Filed 03/25/1987
|
Current Assignee
Shin-Etsu Chemical Company Limited
|
Original Assignee
Shin-Etsu Chemical Company Limited
|
Volume independent diagnostic device | ||
Patent #
US 4,810,470 A
Filed 06/19/1987
|
Current Assignee
Miles Inc.
|
Original Assignee
Miles Inc.
|
Method and membrane applicable to implantable sensor | ||
Patent #
US 4,650,547 A
Filed 12/20/1985
|
Current Assignee
Regents of the University of California
|
Original Assignee
Regents of the University of California
|
Drug dispensing body implantable lead employing molecular sieves and methods of fabrication | ||
Patent #
US 4,577,642 A
Filed 02/27/1985
|
Current Assignee
Medtronic Incorporated
|
Original Assignee
Medtronic Incorporated
|
Drug dispensing body implantable lead | ||
Patent #
US 4,506,680 A
Filed 03/17/1983
|
Current Assignee
Medtronic Incorporated
|
Original Assignee
Medtronic Incorporated
|
Implantable glucose sensor | ||
Patent #
US 4,431,004 A
Filed 10/27/1981
|
Current Assignee
Ennis C. Layne, Samuel P. Bessman, Lyell J. Thomas
|
Original Assignee
Ennis C. Layne, Samuel P. Bessman, Lyell J. Thomas
|
Monitor for continuous in vivo measurement of glucose concentration | ||
Patent #
US 4,436,094 A
Filed 01/27/1982
|
Current Assignee
EVEKA INC 16 FOSTER ST BERGENFIED NJ 07621 A NJ CORP
|
Original Assignee
Evreka Inc.
|
Oxygen stabilized enzyme electrode | ||
Patent #
US 4,374,013 A
Filed 03/03/1981
|
Current Assignee
Sven-Olof Enfors
|
Original Assignee
Sven-Olof Enfors
|
Vibration resistant electrochemical cell having deformed casing and method of making same | ||
Patent #
US 4,255,500 A
Filed 03/29/1979
|
Current Assignee
Gates Energy Products Inc.
|
Original Assignee
General Electric Company
|
Implantable temperature probe | ||
Patent #
US 4,253,469 A
Filed 04/20/1979
|
Current Assignee
Lockheed Martin Corporation
|
Original Assignee
The Narda Microwave Corp.
|
Electrochemical measuring electrode | ||
Patent #
US 4,256,561 A
Filed 05/08/1979
|
Current Assignee
Dr Eduard Fresenius Chemisch-Pharmazeutische Industrie KG Apparatebau KG
|
Original Assignee
DR. EDUARD FRESENIUS CHEMISCH-PHARMAZEUTISCHE INDUSTRIE KG APPARATEBAU KG
|
Hydrophilic contact lens made from polysiloxanes which are thermally bonded to polymerizable groups and which contain hydrophilic sidechains | ||
Patent #
US 4,260,725 A
Filed 12/10/1979
|
Current Assignee
Bausch Lomb Incorporated
|
Original Assignee
Bausch Lomb Incorporated
|
Process for preparing cold water-soluble films from PVA by melt extrusion | ||
Patent #
US 4,267,145 A
Filed 08/25/1978
|
Current Assignee
E. I. du Pont de Nemours and Company
|
Original Assignee
E. I. du Pont de Nemours and Company
|
Permanent magnet device for implantation | ||
Patent #
US 4,197,840 A
Filed 09/29/1976
|
Current Assignee
BBC Brown Boveri Company Limited
|
Original Assignee
BBC Brown Boveri Company Limited
|
Polysiloxane hydrogels | ||
Patent #
US 4,136,250 A
Filed 07/20/1977
|
Current Assignee
Ciba-Geigy Corporation
|
Original Assignee
Ciba-Geigy Corporation
|
Membrane for enzyme electrodes | ||
Patent #
US 4,073,713 A
Filed 07/26/1976
|
Current Assignee
The Yellow Springs Instrument Company Inc.
|
Original Assignee
THE YELLOW SPRINGS INSTRUMENT COMPANY INC.
|
Method of producing porous plastic materials | ||
Patent #
US 4,076,656 A
Filed 07/20/1973
|
Current Assignee
DeBell Richardson Inc.
|
Original Assignee
DEBELL RICHARDSON INC.
|
Disposable physiological telemetric device | ||
Patent #
US 3,943,918 A
Filed 12/02/1971
|
Current Assignee
Tel-Pac Inc.
|
Original Assignee
TEL-PAC INC.
|
POLYSILOXANE-POLYURETHANE BLOCK COPOLYMERS | ||
Patent #
US 3,562,352 A
Filed 09/06/1968
|
Current Assignee
KONTROL CARDIOVASCULAR INC.
|
Original Assignee
Nyilas Emery
|
Lubricating oils thickened with metal salts of cyanuric acid | ||
Patent #
US 2,830,020 A
Filed 10/01/1956
|
Current Assignee
Ludwig J. Christmann, William G. Deichert
|
Original Assignee
Ludwig J. Christmann, William G. Deichert
|
44 Claims
- 1. A membrane layer for use in an analyte sensor, comprising a blend of a silicone polymer with a co-polymer comprising a polymeric hydrophobic domain and a polymeric hydrophilic domain, wherein the membrane is adapted to permit diffusion of both the analyte and oxygen therethrough.
-
9. An implantable analyte sensor, comprising:
-
an electrode adapted to directly or indirectly detect the analyte; and
at least one membrane layer positioned over the electrode comprising a blend of a silicone polymer with a co-polymer comprising a polymeric hydrophobic domain and a polymeric hydrophilic domain. - View Dependent Claims (10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)
-
-
30. An implantable analyte sensor, comprising:
-
an enzyme layer comprising an enzyme for which the analyte is a substrate; and
a bioprotective layer positioned between the enzyme layer and tissue adjacent to the sensor when implanted, wherein the bioprotective layer comprises a blend of a silicone polymer with a co-polymer comprising a polymeric hydrophobic domain and a polymeric hydrophilic domain. - View Dependent Claims (31, 32, 33, 34, 35)
-
-
36. An implantable analyte sensor, comprising:
-
an enzyme layer comprising an enzyme for which the analyte is a substrate; and
a diffusion resistance layer positioned between the enzyme layer and tissue adjacent to the sensor when implanted, wherein the diffusion resistance layer comprises a blend of a silicone polymer with a co-polymer comprising a polymeric hydrophobic domain and a polymeric hydrophilic domain. - View Dependent Claims (37, 38, 39, 40, 41, 42, 43, 44)
-
1 Specification
This application is a continuation-in-part of U.S. application Ser. No. 10/153,356, filed May 22, 2002 and published in Publication No. 2003/0217966, and a continuation-in-part of U.S. application Ser. No. 10/896,639, filed Jul. 21, 2004 and published in Publication No. 2005/0054909, which claims the benefit of U.S. Provisional Application No. 60/490,009, filed Jul. 25, 2003, all of which are incorporated herein by reference in their entirety. This Application is also related to U.S. Application No. ______ attorney docket number DEXCOM.075A, entitled “SILICONE BASED MEMBRANES FOR USE IN IMPLANTABLE GLUCOSE SENSORS,” filed on even date herewith, which is incorporated herein by reference in its entirety.
1. Field of the Invention
The invention relates to membranes for use in implantable analyte sensors (e.g., glucose sensors).
2. Description of the Related Art
Electrochemical sensors are useful in chemistry and medicine to determine the presence or concentration of a biological analyte. Such sensors are useful, for example, to monitor glucose in diabetic patients and lactate during critical care events.
Diabetes mellitus is a disorder in which the pancreas cannot create sufficient insulin (Type I or insulin dependent) and/or in which insulin is not effective (Type 2 or non-insulin dependent). In the diabetic state, the victim suffers from high blood sugar, which causes an array of physiological derangements (kidney failure, skin ulcers, or bleeding into the vitreous of the eye) associated with the deterioration of small blood vessels. A hypoglycemic reaction (low blood sugar) is induced by an inadvertent overdose of insulin, or after a normal dose of insulin or glucose-lowering agent accompanied by extraordinary exercise or insufficient food intake.
Conventionally, a diabetic person carries a self-monitoring blood glucose (SMBG) monitor, which typically utilizes uncomfortable finger pricking methods. Due to the lack of comfort and convenience, a diabetic normally only measures his or her glucose level two to four times per day. Unfortunately, these time intervals are spread so far apart that the diabetic likely finds out too late, sometimes incurring dangerous side effects, of a hyperglycemic or hypoglycemic condition. In fact, it is not only unlikely that a diabetic will take a timely SMBG value, but additionally the diabetic will not know if their blood glucose value is going up (higher) or down (lower) based on conventional methods.
Consequently, a variety of transdermal and implantable electrochemical sensors are being developed for continuously detecting and/or quantifying blood glucose values. Many implantable glucose sensors suffer from complications within the body and provide only short-term or less-than-accurate sensing of blood glucose. Similarly, transdermal sensors have problems in accurately sensing and reporting back glucose values continuously over extended periods of time. Some efforts have been made to obtain blood glucose data from implantable devices and retrospectively determine blood glucose trends for analysis; however these efforts do not aid the diabetic in determining real-time blood glucose information. Some efforts have also been made to obtain blood glucose data from transdermal devices for prospective data analysis, however similar problems have been observed.
One embodiment disclosed herein includes a membrane layer for use in an analyte sensor, the membrane layer including a blend of a silicone polymer with a co-polymer comprising a polymeric hydrophobic domain and a polymeric hydrophilic domain, wherein the membrane is adapted to permit diffusion of both the analyte and oxygen therethrough. In one embodiment, the silicone polymer is a dimethyl- and methylhydrogen-siloxane copolymer. In one embodiment, the silicone polymer comprises vinyl substituents. In one embodiment, the silicone polymer is a polymer produced by curing a MED-4840 mixture. In one embodiment, the co-polymer comprises poly(ethylene oxide) and poly(propylene oxide). In one embodiment, the copolymer comprises hydroxy substituents. In one embodiment, the analyte is glucose. In one embodiment, at least a portion of the co-polymer is cross-linked.
Another embodiment disclosed herein includes an implantable analyte sensor, including an electrode adapted to directly or indirectly detect the analyte and at least one membrane layer positioned over the electrode comprising a blend of a silicone polymer with a co-polymer comprising a polymeric hydrophobic domain and a polymeric hydrophilic domain. In one embodiment, the sensor includes an enzyme layer positioned over the electrode, the enzyme layer comprising an enzyme for which the analyte is a substrate. In one embodiment, the enzyme layer is one of the at least one membrane layer. In one embodiment, one of the at least one membrane layer is positioned between the enzyme layer and tissue adjacent to the sensor when implanted. In one embodiment, the sensor includes a diffusion resistance layer positioned between the enzyme layer and tissue adjacent to the sensor when implanted. In one embodiment, at least one of the enzyme layer and the diffusion resistance layer is one of the at least one membrane layer. In one embodiment, the diffusion resistance layer is one of the at least one membrane layer. In one embodiment, the sensor includes a bioprotective layer positioned between the diffusion resistance layer and tissue adjacent to the sensor when implanted. In one embodiment, at least one of the enzyme layer, the diffusion resistance layer, and the bioprotective layer is one of the at least one membrane layer. In one embodiment, the bioprotective layer is one of the at least one membrane layer. In one embodiment, a cell disruptive layer is positioned between the bioprotective layer and tissue adjacent to the sensor when implanted. In one embodiment, at least one of the enzyme layer, the bioprotective layer, the diffusion resistance layer, and the cell disruptive layer is one of the at least one membrane layer. In one embodiment, the cell disruptive layer is one of the at least one membrane layer. In one embodiment, the cell disruptive layer is substantially porous. In one embodiment, the cell disruptive layer is a silicone polymer. In one embodiment, the sensor includes an electrode layer positioned between the electrode and the enzyme layer, wherein the electrode layer is adapted to maintain a layer of aqueous electrolyte at the electrode'"'"'s surface. In one embodiment, at least one of the enzyme layer, the bioprotective layer, the diffusion resistance layer, the cell disruptive layer, and the electrode layer is one of the at least one membrane layer. In one embodiment, the electrode layer is one of the at least one membrane layer. In one embodiment, the electrode layer comprises a hydrogel. In one embodiment, the silicone polymer is a dimethyl- and methylhydrogen-siloxane copolymer. In one embodiment, the silicone polymer comprises vinyl substituents. In one embodiment, the silicone polymer is a polymer produced by curing a MED-4840 mixture. In one embodiment, the co-polymer comprises poly(ethylene oxide) and poly(propylene oxide). In one embodiment, the copolymer comprises hydroxy substituents. In one embodiment, the co-polymer is a triblock poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) polymer. In one embodiment, the co-polymer is a triblock poly(propylene oxide)-poly(ethylene oxide)-poly(propylene oxide) polymer. In one embodiment, the co-polymer is a PLURONIC® polymer. In one embodiment, the co-polymer is PLURONIC® F-127. In one embodiment, the analyte is glucose. In one embodiment, at least a portion of the co-polymer is cross-linked. In one embodiment, the sensor is configured to be wholly implanted.
Another embodiment disclosed herein includes an implantable analyte sensor, including an enzyme layer comprising an enzyme for which the analyte is a substrate and a bioprotective layer positioned between the enzyme layer and tissue adjacent to the sensor when implanted, wherein the bioprotective layer comprises a blend of a silicone polymer with a co-polymer comprising a polymeric hydrophobic domain and a polymeric hydrophilic domain. One embodiment further includes a diffusion resistance layer positioned between the enzyme layer and the bioprotective layer. In one embodiment, the diffusion resistance layer also comprises a blend of the silicone polymer with the co-polymer, wherein the ratio of the silicone polymer to the co-polymer is different in the diffusion resistance layer than in the bioprotective layer. In one embodiment, the sensor does not comprise an additional diffusion resistance layer and the bioprotective layer is adapted to have diffusion resistance characteristics. In one embodiment, the silicone polymer is a dimethyl- and methylhydrogen-siloxane copolymer. In one embodiment, the silicone polymer comprises vinyl substituents. In one embodiment, the silicone polymer is a polymer produced by curing a MED-4840 mixture. In one embodiment, the co-polymer comprises poly(ethylene oxide) and poly(propylene oxide). In one embodiment, the copolymer comprises hydroxy substituents. In one embodiment, the analyte is glucose. In one embodiment, at least a portion of the co-polymer is cross-linked. In one embodiment, at least a portion of the bioprotective layer is porous and adjacent to tissue when implanted. In one embodiment, the ratio of the silicone elastomer to co-polymer varies within the bioprotective layer. In one embodiment, the sensor is configured to be wholly implanted.
Another embodiment disclosed herein includes an implantable analyte sensor, including an enzyme layer comprising an enzyme for which the analyte is a substrate and a diffusion resistance layer positioned between the enzyme layer and tissue adjacent to the sensor when implanted, wherein the diffusion resistance layer comprises a blend of a silicone polymer with a co-polymer comprising a polymeric hydrophobic domain and a polymeric hydrophilic domain. In one embodiment, at least a portion of the diffusion resistance layer is porous and adjacent to tissue when implanted. In one embodiment, the ratio of the silicone elastomer to co-polymer varies within the diffusion resistance layer. One embodiment further includes a bioprotective layer positioned between the diffusion resistance layer and tissue adjacent to the sensor when implanted. In one embodiment, the bioprotective layer also comprises a blend of the silicone polymer with the co-polymer, wherein the ratio of the silicone polymer to the co-polymer is different in the diffusion resistance layer than in the bioprotective layer. In one embodiment, the sensor does not comprise an additional bioprotective layer and the diffusion resistance layer is adapted to have bioprotective characteristics. One embodiment further includes a silicone cell disruptive layer positioned between the diffusion resistance layer and tissue adjacent to the sensor when implanted. In one embodiment, the silicone polymer is a dimethyl- and methylhydrogen-siloxane copolymer. In one embodiment, the silicone polymer comprises vinyl substituents. In one embodiment, the silicone polymer is a polymer produced by curing a MED-4840 mixture. In one embodiment, the co-polymer comprises poly(ethylene oxide) and poly(propylene oxide). In one embodiment, the copolymer comprises hydroxy substituents. In one embodiment, the analyte is glucose. In one embodiment, at least a portion of the co-polymer is cross-linked. In one embodiment, the sensor is configured to be wholly implanted.
The following description and examples illustrate some exemplary embodiments of the disclosed invention in detail. Those of skill in the art will recognize that there are numerous variations and modifications of this invention that are encompassed by its scope. Accordingly, the description of a certain exemplary embodiment should not be deemed to limit the scope of the present invention.
In order to facilitate an understanding of the preferred embodiments, a number of terms are defined below.
The term “analyte” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a substance or chemical constituent in a biological fluid (for example, blood, interstitial fluid, cerebral spinal fluid, lymph fluid or urine) that can be analyzed. Analytes can include naturally occurring substances, artificial substances, metabolites, and/or reaction products. In some embodiments, the analyte for measurement by the sensing regions, devices, and methods is glucose. However, other analytes are contemplated as well, including but not limited to acarboxyprothrombin; acylcarnitine; adenine phosphoribosyl transferase; adenosine deaminase; albumin; alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, tryptophan); andrenostenedione; antipyrine; arabinitol enantiomers; arginase; benzoylecgonine (cocaine); biotinidase; biopterin; c-reactive protein; carnitine; carnosinase; CD4; ceruloplasmin; chenodeoxycholic acid; chloroquine; cholesterol; cholinesterase; conjugated 1-β hydroxy-cholic acid; cortisol; creatine kinase; creatine kinase MM isoenzyme; cyclosporin A; d-penicillamine; de-ethylchloroquine; dehydroepiandrosterone sulfate; DNA (acetylator polymorphism, alcohol dehydrogenase, alpha 1-antitrypsin, cystic fibrosis, Duchenne/Becker muscular dystrophy, glucose-6-phosphate dehydrogenase, hemoglobin A, hemoglobin S, hemoglobin C, hemoglobin D, hemoglobin E, hemoglobin F, D-Punjab, beta-thalassemia, hepatitis B virus, HCMV, HIV-1, HTLV-1, Leber hereditary optic neuropathy, MCAD, RNA, PKU, Plasmodium vivax, sexual differentiation, 21-deoxycortisol); desbutylhalofantrine; dihydropteridine reductase; diptheria/tetanus antitoxin; erythrocyte arginase; erythrocyte protoporphyrin; esterase D; fatty acids/acylglycines; free β-human chorionic gonadotropin; free erythrocyte porphyrin; free thyroxine (FT4); free tri-iodothyronine (FT3); fumarylacetoacetase; galactose/gal-1-phosphate; galactose-1-phosphate uridyltransferase; gentamicin; glucose-6-phosphate dehydrogenase; glutathione; glutathione perioxidase; glycocholic acid; glycosylated hemoglobin; halofantrine; hemoglobin variants; hexosaminidase A; human erythrocyte carbonic anhydrase I; 17-alpha-hydroxyprogesterone; hypoxanthine phosphoribosyl transferase; immunoreactive trypsin; lactate; lead; lipoproteins ((a), B/A-1, β); lysozyme; mefloquine; netilmicin; phenobarbitone; phenytoin; phytanic/pristanic acid; progesterone; prolactin; prolidase; purine nucleoside phosphorylase; quinine; reverse tri-iodothyronine (rT3); selenium; serum pancreatic lipase; sissomicin; somatomedin C; specific antibodies (adenovirus, anti-nuclear antibody, anti-zeta antibody, arbovirus, Aujeszky'"'"'s disease virus, dengue virus, Dracunculus medinensis, Echinococcus granulosus, Entamoeba histolytica, enterovirus, Giardia duodenalisa, Helicobacter pylori, hepatitis B virus, herpes virus, HIV-1, IgE (atopic disease), influenza virus, Leishmania donovani, leptospira, measles/mumps/rubella, Mycobacterium leprae, Mycoplasma pneumoniae, Myoglobin, Onchocerca volvulus, parainfluenza virus, Plasmodium falciparum, poliovirus, Pseudomonas aeruginosa, respiratory syncytial virus, rickettsia (scrub typhus), Schistosoma mansoni, Toxoplasma gondii, Trepenoma pallidium, Trypanosoma cruzi/rangeli, vesicular stomatis virus, Wuchereria bancrofti, yellow fever virus); specific antigens (hepatitis B virus, HIV-1); succinylacetone; sulfadoxine; theophylline; thyrotropin (TSH); thyroxine (T4); thyroxine-binding globulin; trace elements; transferrin; UDP-galactose-4-epimerase; urea; uroporphyrinogen I synthase; vitamin A; white blood cells; and zinc protoporphyrin. Salts, sugar, protein, fat, vitamins, and hormones naturally occurring in blood or interstitial fluids can also constitute analytes in certain embodiments. The analyte can be naturally present in the biological fluid or endogenous, for example, a metabolic product, a hormone, an antigen, an antibody, and the like. Alternatively, the analyte can be introduced into the body or exogenous, for example, a contrast agent for imaging, a radioisotope, a chemical agent, a fluorocarbon-based synthetic blood, or a drug or pharmaceutical composition, including but not limited to insulin; ethanol; cannabis (marijuana, tetrahydrocannabinol, hashish); inhalants (nitrous oxide, amyl nitrite, butyl nitrite, chlorohydrocarbons, hydrocarbons); cocaine (crack cocaine); stimulants (amphetamines, methamphetamines, Ritalin, Cylert, Preludin, Didrex, PreState, Voranil, Sandrex, Plegine); depressants (barbituates, methaqualone, tranquilizers such as Valium, Librium, Miltown, Serax, Equanil, Tranxene); hallucinogens (phencyclidine, lysergic acid, mescaline, peyote, psilocybin); narcotics (heroin, codeine, morphine, opium, meperidine, Percocet, Percodan, Tussionex, Fentanyl, Darvon, Talwin, Lomotil); designer drugs (analogs of fentanyl, meperidine, amphetamines, methamphetamines, and phencyclidine, for example, Ecstasy); anabolic steroids; and nicotine. The metabolic products of drugs and pharmaceutical compositions are also contemplated analytes. Analytes such as neurochemicals and other chemicals generated within the body can also be analyzed, such as, for example, ascorbic acid, uric acid, dopamine, noradrenaline, 3-methoxytyramine (3MT), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxytryptamine (5HT), and 5-hydroxyindoleacetic acid (FHIAA).
The terms “operable connection,” “operably connected,” and “operably linked” as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to one or more components linked to another component(s) in a manner that allows transmission of signals between the components. For example, one or more electrodes can be used to detect the amount of analyte in a sample and convert that information into a signal; the signal can then be transmitted to a circuit. In this case, the electrode is “operably linked” to the electronic circuitry.
The term “host” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to animals and plants, for example humans.
The terms “electrochemically reactive surface” and “electroactive surface” as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to the surface of an electrode where an electrochemical reaction takes place. As one example, a working electrode measures hydrogen peroxide produced by the enzyme catalyzed reaction of the analyte being detected reacts creating an electric current (for example, detection of glucose analyte utilizing glucose oxidase produces H2O2 as a by product, H2O2 reacts with the surface of the working electrode producing two protons (2H+), two electrons (2e−) and one molecule of oxygen (O2) which produces the electronic current being detected). In the case of the counter electrode, a reducible species, for example, O2 is reduced at the electrode surface in order to balance the current being generated by the working electrode.
The term “sensing region” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the region of a monitoring device responsible for the detection of a particular analyte. The sensing region generally comprises a non-conductive body, a working electrode, a reference electrode, and/or a counter electrode (optional) passing through and secured within the body forming electrochemically reactive surfaces on the body, an electronic connective means at another location on the body, and a multi-domain membrane affixed to the body and covering the electrochemically reactive surface.
The terms “raw data stream” and “data stream” as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to an analog or digital signal directly related to the measured glucose concentration from the glucose sensor. In one example, the raw data stream is digital data in “counts” converted by an A/D converter from an analog signal (for example, voltage or amps) representative of a glucose concentration. The terms broadly encompass a plurality of time spaced data points from a substantially continuous glucose sensor, which comprises individual measurements taken at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes or longer.
The term “counts” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a unit of measurement of a digital signal. In one example, a raw data stream measured in counts is directly related to a voltage (for example, converted by an A/D converter), which is directly related to current from the working electrode. In another example, counter electrode voltage measured in counts is directly related to a voltage.
The term “electrical potential” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the electrical potential difference between two points in a circuit which is the cause of the flow of a current.
The term “ischemia” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to local and temporary deficiency of blood supply due to obstruction of circulation to a part (for example, sensor). lschemia can be caused by mechanical obstruction (for example, arterial narrowing or disruption) of the blood supply, for example.
The term “system noise” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to unwanted electronic or diffusion-related noise which can include Gaussian, motion-related, flicker, kinetic, or other white noise, for example.
The terms “signal artifacts” and “transient non-glucose related signal artifacts,” as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to signal noise that is caused by substantially non-glucose reaction rate-limiting phenomena, such as ischemia, pH changes, temperature changes, pressure, and stress, for example. Signal artifacts, as described herein, are typically transient and are characterized by higher amplitude than system noise.
The terms “low noise” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to noise that substantially decreases signal amplitude.
The terms “high noise” and “high spikes” as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to noise that substantially increases signal amplitude.
The term “silicone composition” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a composition of matter that comprises polymers having at least silicon and oxygen atoms in the backbone.
The phrase “distal to” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the spatial relationship between various elements in comparison to a particular point of reference. For example, some embodiments of a device include a membrane system having a cell disruptive domain and a cell impermeable domain. If the sensor is deemed to be the point of reference and the cell disruptive domain.is positioned farther from the sensor, then that domain is distal to the sensor.
The phrase “proximal to” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the spatial relationship between various elements in comparison to a particular point of reference. For example, some embodiments of a device include a membrane system having a cell disruptive domain and a cell impermeable domain. If the sensor is deemed to be the point of reference and the cell impermeable domain is positioned nearer to the sensor, then that domain is proximal to the sensor.
The terms “interferants” and “interfering species” as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to effects and/or species that interfere with the measurement of an analyte of interest in a sensor to produce a signal that does not accurately represent the analyte measurement. In an exemplary electrochemical sensor, interfering species can include compounds with an oxidation potential that overlaps with that of the analyte to be measured.
As employed herein, the following abbreviations apply: Eq and Eqs (equivalents); mEq (milliequivalents); M (molar); mM (millimolar) μM (micromolar); N (Normal); mol (moles); mmol (millimoles); μmol (micromoles); nmol (nanomoles); g (grams); mg (milligrams); μg (micrograms); Kg (kilograms); L (liters); mL (milliliters); dL (deciliters); μL (microliters); cm (centimeters); mm (millimeters); μm (micrometers); nm (nanometers); h and hr (hours); min. (minutes); s and sec. (seconds); ° C. (degrees Centigrade).
Overview
Membrane systems of the preferred embodiments are suitable for use with implantable devices in contact with a biological fluid. For example, the membrane systems can be utilized with implantable devices such as devices for monitoring and determining analyte levels in a biological fluid, for example, glucose levels for individuals having diabetes. In some embodiments, the analyte-measuring device is a continuous device. Alternatively, the device can analyze a plurality of intermittent biological samples. The analyte-measuring device can use any method of analyte-measurement, including enzymatic, chemical, physical, electrochemical, spectrophotometric, polarimetric, calorimetric, radiometric, or the like.
Although some of the description that follows is directed at glucose-measuring devices, including the described membrane systems and methods for their use, these membrane systems are not limited to use in devices that measure or monitor glucose. These membrane systems are suitable for use in a variety of devices, including, for example, those that detect and quantify other analytes present in biological fluids (including, but not limited to, cholesterol, amino acids, alcohol, galactose, and lactate), cell transplantation devices (see, for example, U.S. Pat. Nos. 6,015,572, 5,964,745, and 6,083,523), drug delivery devices (see, for example, U.S. Pat. Nos. 5,458,631, 5,820,589, and 5,972,369), and the like. Preferably, implantable devices that include the membrane systems of the preferred embodiments are implanted in soft tissue, for example, abdominal, subcutaneous, and peritoneal tissues, the brain, the intramedullary space, and other suitable organs or body tissues.
In addition to the glucose-measuring device described below, the membrane systems of the preferred embodiments can be employed with a variety of known glucose measuring-devices. In some embodiments, the electrode system can be used with any of a variety of known in vivo analyte sensors or monitors, such as U.S. Pat. No. 6,001,067 to Shults et al.; U.S. Pat. No. 6,702,857 to Brauker et al.; U.S. Pat. No. 6,212,416 to Ward et al.; U.S. Pat. No. 6,119,028 to Schulman et al.; U.S. Pat. No. 6,400,974 to Lesho; U.S. Pat. No. 6,595,919 to Berner et al.; U.S. Pat. No. 6,141,573 to Kurnik et al.; U.S. Pat. No. 6,122,536 to Sun et al.; European Patent Application EP 1153571 to Varall et al.; U.S. Pat. No. 6,512,939 to Colvin et al.; U.S. Pat. No. 5,605,152 to Slate et al.; U.S. Pat. No. 4,431,004 to Bessman et al.; U.S. Pat. No. 4,703,756 to Gough et al.; U.S. Pat. No. 6,514,718 to Heller et al.; U.S. Pat. No. 5,985,129 to Gough et al.; WO Patent Application Publication No. 04/021877 to Caduff; U.S. Pat. No. 5,494,562 to Maley et al.; U.S. Pat. No. 6,120,676 to Heller et al.; and U.S. Pat. No. 6,542,765 to Guy et al., each of which are incorporated in there entirety herein by reference. In general, it is understood that the disclosed embodiments are applicable to a variety of continuous glucose measuring device configurations.
In this embodiment, the electrode system 16 is operably connected to the sensor electronics (
The membrane system 18 of the preferred embodiments, which are described in more detail below with reference to
In some embodiments, the electrode system 16, which is located on or within the sensing region 14, is comprised of at least a working and a reference electrode with an insulating material disposed therebetween. In some alternative embodiments, additional electrodes can be included within the electrode system, for example, a three-electrode system (working, reference, and counter electrodes) and/or including an additional working electrode (which can be used to generate oxygen, measure an additional analyte, or can be configured as a baseline subtracting electrode, for example).
In the exemplary embodiment of
- GOX+Glucose+O2→Gluconate+H2O2+reduced GOX
The change in H2O2 can be monitored to determine glucose concentration because for each glucose molecule metabolized, there is a proportional change in the product H2O2. Oxidation of H2O2 by the working electrode is balanced by reduction of ambient oxygen, enzyme generated H2O2, or other reducible species at the counter electrode. The H2O2 produced from the glucose oxidase reaction further reacts at the surface of working electrode and produces two protons (2H+), two electrons (2e−), and one oxygen molecule (O2). In such embodiments, because the counter electrode utilizes oxygen as an electron acceptor, the most likely reducible species for this system are oxygen or enzyme generated peroxide. There are two main pathways by which oxygen can be consumed at the counter electrode. These pathways include a four-electron pathway to produce hydroxide and a two-electron pathway to produce hydrogen peroxide. In addition to the counter electrode, oxygen is further consumed by the reduced glucose oxidase within the enzyme domain. Therefore, due to the oxygen consumption by both the enzyme and the counter electrode, there is a net consumption of oxygen within the electrode system. Theoretically, in the domain of the working electrode there is significantly less net loss of oxygen than in the region of the counter electrode. In addition, there is a close correlation between the ability of the counter electrode to maintain current balance and sensor function.
In general, in electrochemical sensors wherein an enzymatic reaction depends on oxygen as a co-reactant, depressed function or inaccuracy can be experienced in low oxygen environments, for example in vivo. Subcutaneously implanted devices are especially susceptible to transient ischemia that can compromise device function; for example, because of the enzymatic reaction required for an implantable amperometric glucose sensor, oxygen must be in excess over glucose in order for the sensor to effectively function as a glucose sensor. If glucose becomes in excess, the sensor turns into an oxygen sensitive device. In vivo, glucose concentration can vary from about one hundred times or more that of the oxygen concentration. Consequently, oxygen becomes a limiting reactant in the electrochemical reaction and when insufficient oxygen is provided to the sensor, the sensor is unable to accurately measure glucose concentration. Those skilled in the art interpret oxygen limitations resulting in depressed function or inaccuracy as a problem of availability of oxygen to the enzyme and/or counter electrode. Oxygen limitations can also be seen during periods of transient ischemia that occur, for example, under certain postures or when the region around the implanted sensor is compressed so that blood is forced out of the capillaries. Such ischemic periods observed in implanted sensors can last for many minutes or even an hour or longer.
An A/D converter 136 digitizes the analog signal into a digital signal, also referred to as “counts” for processing. Accordingly, the resulting raw data stream in counts, also referred to as raw sensor data, is directly related to the current measured by the potentiostat 134.
A processor module 138 includes the central control unit that controls the processing of the sensor electronics 132. In some embodiments, the processor module includes a microprocessor, however a computer system other than a microprocessor can be used to process data as described herein, for example an ASIC can be used for some or all of the sensor'"'"'s central processing. The processor typically provides semi-permanent storage of data, for example, storing data such as sensor identifier (ID) and programming to process data streams (for example, programming for data smoothing and/or replacement of signal artifacts such as is described in U.S. Publication No. US-2005-0043598-A1). The processor additionally can be used for the system'"'"'s cache memory, for example for temporarily storing recent sensor data. In some embodiments, the processor module comprises memory storage components such as ROM, RAM, dynamic-RAM, static-RAM, non-static RAM, EEPROM, rewritable ROMs, flash memory, or the like.
In some embodiments, the processor module comprises a digital filter, for example, an infinite impulse response (IIR) or finite impulse response (FIR) filter, configured to smooth the raw data stream from the A/D converter. Generally, digital filters are programmed to filter data sampled at a predetermined time interval (also referred to as a sample rate). In some embodiments, wherein the potentiostat is configured to measure the analyte at discrete time intervals, these time intervals determine the sample rate of the digital filter. In some alternative embodiments, wherein the potentiostat is configured to continuously measure the analyte, for example, using a current-to-frequency converter as described above, the processor module can be programmed to request a digital value from the A/D converter at a predetermined time interval, also referred to as the acquisition time. In these alternative embodiments, the values obtained by the processor are advantageously averaged over the acquisition time due the continuity of the current measurement. Accordingly, the acquisition time determines the sample rate of the digital filter. In preferred embodiments, the processor module is configured with a programmable acquisition time, namely, the predetermined time interval for requesting the digital value from the A/D converter is programmable by a user within the digital circuitry of the processor module. An acquisition time of from about 2 seconds to about 512 seconds is preferred; however any acquisition time can be programmed into the processor module. A programmable acquisition time is advantageous in optimizing noise filtration, time lag, and processing/battery power.
Preferably, the processor module is configured to build the data packet for transmission to an outside source, for example, an RF transmission to a receiver as described in more detail below. Generally, the data packet comprises a plurality of bits that can include a preamble, a unique identifier identifying the electronics unit, the receiver, or both, (e.g., sensor ID code), data (e.g., raw data, filtered data, and/or an integrated value) and/or error detection or correction. Preferably, the data (transmission) packet has a length of from about 8 bits to about 128 bits, preferably about 48 bits; however, larger or smaller packets can be desirable in certain embodiments. The processor module can be configured to transmit any combination of raw and/or filtered data. In one exemplary embodiment, the transmission packet contains a fixed preamble, a unique ID of the electronics unit, a single five-minute average (e.g., integrated) sensor data value, and a cyclic redundancy code (CRC).
In some embodiments, the processor module further comprises a transmitter portion that determines the transmission interval of the sensor data to a receiver, or the like. In some embodiments, the transmitter portion, which determines the interval of transmission, is configured to be programmable. In one such embodiment, a coefficient can be chosen (e.g., a number of from about 1 to about 100, or more), wherein the coefficient is multiplied by the acquisition time (or sampling rate), such as described above, to define the transmission interval of the data packet. Thus, in some embodiments, the transmission interval is programmable from about 2 seconds to about 850 minutes, more preferably from about 30 second to about 5 minutes; however, any transmission interval can be programmable or programmed into the processor module. However, a variety of alternative systems and methods for providing a programmable transmission interval can also be employed. By providing a programmable transmission interval, data transmission can be customized to meet a variety of design criteria (e.g., reduced battery consumption, timeliness of reporting sensor values, etc.)
Conventional glucose sensors measure current in the nanoAmp range. In some embodiments, the preferred embodiments are configured to measure the current flow in the picoAmp range, and in some embodiments, femtoAmps. Namely, for every unit (mg/dL) of glucose measured, at least one picoAmp of current is measured. Preferably, the analog portion of the A/D converter 136 is configured to continuously measure the current flowing at the working electrode and to convert the current measurement to digital values representative of the current. In one embodiment, the current flow is measured by a charge counting device (e.g., a capacitor). Preferably, a charge counting device provides a value (e.g., digital value) representative of the current flow integrated over time (e.g., integrated value). In some embodiments, the value is integrated over a few seconds, a few minutes, or longer. In one exemplary embodiment, the value is integrated over 5 minutes; however, other integration periods can be chosen. Thus, a signal is provided, whereby a high sensitivity maximizes the signal received by a minimal amount of measured hydrogen peroxide (e.g., minimal glucose requirements without sacrificing accuracy even in low glucose ranges), reducing the sensitivity to oxygen limitations in vivo (e.g., in oxygen-dependent glucose sensors).
In some embodiments, the electronics unit is programmed with a specific ID, which is programmed (automatically or by the user) into a receiver to establish a secure wireless communication link between the electronics unit and the receiver. Preferably, the transmission packet is Manchester encoded; however, a variety of known encoding techniques can also be employed.
A battery 154 is operably connected to the sensor electronics 132 and provides the power for the sensor. In one embodiment, the battery is a lithium manganese dioxide battery; however, any appropriately sized and powered battery can be used (for example, AAA, nickel-cadmium, zinc-carbon, alkaline, lithium, nickel-metal hydride, lithium-ion, zinc-air, zinc-mercury oxide, silver-zinc, and/or hermetically-sealed). In some embodiments, the battery is rechargeable, and/or a plurality of batteries can be used to power the system. The sensor can be transcutaneously powered via an inductive coupling, for example. In some embodiments, a quartz crystal 96 is operably connected to the processor 138 and maintains system time for the computer system as a whole, for example for the programmable acquisition time within the processor module.
Optional temperature probe 140 is shown, wherein the temperature probe is located on the electronics assembly or the glucose sensor itself. The temperature probe can be used to measure ambient temperature in the vicinity of the glucose sensor. This temperature measurement can be used to add temperature compensation to the calculated glucose value.
An RF module 158 is operably connected to the processor 138 and transmits the sensor data from the sensor to a receiver within a wireless transmission 160 via antenna 152. In some embodiments, a second quartz crystal 154 provides the time base for the RF carrier frequency used for data transmissions from the RF transceiver. In some alternative embodiments, however, other mechanisms, such as optical, infrared radiation (IR), ultrasonic, or the like, can be used to transmit and/or receive data.
In the RF telemetry module of the preferred embodiments, the hardware and software are designed for low power requirements to increase the longevity of the device (for example, to enable a life of from about 3 to about 24 months, or more) with maximum RF transmittance from the in vivo environment to the ex vivo environment for wholly implantable sensors (for example, a distance of from about one to ten meters or more). Preferably, a high frequency carrier signal of from about 402 MHz to about 433 MHz is employed in order to maintain lower power requirements. In some embodiments, the RF module employs a one-way RF communication link to provide a simplified ultra low power data transmission and receiving scheme. The RF transmission can be OOK or FSK modulated, preferably with a radiated transmission power (EIRP) fixed at a single power level of typically less than about 100 microwatts, preferably less than about 75 microwatts, more preferably less than about 50 microwatts, and most preferably less than about 25 microwatts.
Additionally, in wholly implantable devices, the carrier frequency may be adapted for physiological attenuation levels, which is accomplished by tuning the RF module in a simulated in vivo environment to ensure RF functionality after implantation; accordingly, the preferred glucose sensor can sustain sensor function for 3 months, 6 months, 12 months, or 24 months or more.
The above description of sensor electronics associated with the electronics unit is applicable to a variety of continuous analyte sensors, such as non-invasive, minimally invasive, and/or invasive (e.g., transcutaneous and wholly implantable) sensors. For example, the sensor electronics and data processing as well as the receiver electronics and data processing described below can be incorporated into the wholly implantable glucose sensor disclosed in U.S. Publication No. US-2005-0245799-A1 and U.S. patent application Ser. No. 10/885,476 filed Jul. 6, 2004 and entitled, “SYSTEMS AND METHODS FOR MANUFACTURE OF AN ANALYTE-MEASURING DEVICE INCLUDING A MEMBRANE SYSTEM.”
In one alternative embodiment, rather than the sensor being wholly implanted, a transcutaneous wire sensor is utilized. For example, one such suitable wire sensor 142 is depicted in
Membrane Systems of the Preferred Embodiments
As described below with reference to
The membrane systems of preferred embodiments are constructed of one or more membrane layers. Each distinct layer can comprise the same or different materials. Furthermore, each layer can be homogenous or alternatively may comprise different domains or gradients where the composition varies.
In some embodiments, the membrane systems for use in implantable sensors is formed as a physically continuous membrane, namely, a membrane having substantially uniform physical structural characteristics from one side of the membrane to the other. However, the membrane can have chemically heterogeneous domains, for example, domains resulting from the use of block copolymers (for example, polymers in which different blocks of identical monomer units alternate with each other), but can be defined as homogeneous overall in that each of the above-described layers functions by the preferential diffusion of some substance through the homogeneous membrane.
Some layers of the membrane systems 18 of the preferred embodiments include materials with high oxygen solubility. In some embodiments, the membrane systems 18 with high oxygen solubility simultaneously permit efficient transport of aqueous solutions of the analyte.
In one embodiment, one or more layer(s) is/are formed from a composition that, in addition to providing high oxygen solubility, allows for the transport of glucose or other such water-soluble molecules (for example, drugs). In one embodiment, one or more layer(s) include (a) a matrix including a first polymer; and (b) a second polymer dispersed throughout the matrix, wherein the second polymer forms a network of microdomains which when hydrated are not observable using photomicroscopy at 400× magnification or less. In one embodiment, the membrane is substantially free of observable domains when hydrated.
In one embodiment, the first polymer includes a homopolymer A and the second polymer includes a copolymer AB. In another embodiment, the first polymer includes a copolymer AB and the second polymer includes a copolymer AB. The amount of B in copolymer AB of the first polymer may be different than the amount of B in copolymer AB of the second polymer. In particular, the layer(s) may be formed from a blend of two AB copolymers, where one of the copolymers contains more of a hydrophilic B polymer component than the blended targeted amount and the other copolymer contains less of a hydrophilic B polymer component than the blended targeted amount.
In yet another embodiment of the invention, the first polymer includes a homopolymer A and the second polymer includes a homopolymer B.
In one embodiment the layer(s) include at least one block copolymer AB, wherein B forms a network of microdomains which are not photomicroscopically observable when hydrated at 400× magnification or less. In one embodiment, the ratio of A to B in copolymer AB is 70:30 to 90:10.
In one embodiment, homopolymer A is a hydrophobic A polymer. In one embodiment, copolymer AB is a hydrophobic-hydrophilic copolymer component that includes the reaction products of a hydrophobic A polymer and a hydrophilic B polymer. Suitable materials for preparing membranes the present invention are described below. The hydrophobic domain(s) of the hydrophobic-hydrophilic polymer facilitate the blending of the copolymer with the hydrophobic A polymer. The hydrophobic domain of the hydrophobic-hydrophilic polymer is not a simple molecular head group but is rather polymeric.
Copolymer AB may be a random or ordered block copolymer. Specifically, the random or ordered block copolymer may be selected from the following: ABA block copolymer, BAB block copolymer, AB random alternating block copolymer, AB regularly alternating block copolymer and combinations thereof.
In one embodiment, the layer(s) are formed from a blend of polymers including (i) a hydrophobic A polymer component; and (ii) a hydrophobic-hydrophilic copolymer component blended with component (i) that forms hydrophilic B domains that control the diffusion of an analyte therethrough, wherein the copolymer component includes a random or ordered block copolymer. One is able to modify the glucose permeability and the glucose diffusion characteristics of the membrane by simply varying the polymer composition.
In one embodiment, the hydrophobic A polymer is a polyurethane. In one embodiment, the polyurethane is polyetherurethaneurea. A polyurethane is a polymer produced by the condensation reaction of a diisocyanate and a difunctional hydroxyl-containing material. A polyurethaneurea is a polymer produced by the condensation reaction of a diisocyanate and a difunctional amine-containing material. Preferred diisocyanates include aliphatic diisocyanates containing from 4 to 8 methylene units. Diisocyanates containing cycloaliphatic moieties, may also be useful in the preparation of the polymer and copolymer components of the membrane of the present invention. In other embodiments, the hydrophobic polymer is selected from vinyl polymers, polyethers, polyesters, polyamides, inorganic polymers such as polysiloxanes and polycarbosiloxanes, natural polymers such as cellulosic and protein based materials and mixtures or combinations thereof.
The hydrophobic-hydrophilic copolymer component may include the reaction products of a hydrophobic A polymer component and a hydrophilic B polymer component. The hydrophilic B polymer component is desirably polyethylene oxide. One hydrophobic-hydrophilic copolymer component is a polyurethane polymer that includes about 20% hydrophilic polyethyelene oxide. The polyethylene oxide portion of the copolymer is thermodynamically driven to separate from the hydrophobic portions of the copolymer and the hydrophobic A polymer component. The 20% polyethylene oxide based soft segment portion of the copolymer used to form the final blend controls the water pick-up and subsequent glucose permeability.
In one embodiment, the polyethylene oxide may have an average molecular weight of from 200 to 3000 with a preferred molecular weight range of 600 to 1500 and preferably constitutes about 20% by weight of the copolymer component used to form the membrane of the present invention.
In one embodiment, the hydrophobic-hydrophilic copolymer is constructed of a polyetherurethaneurea/polyetherurethaneurea-block-polyethylene glycol blend. The hydrophobic-hydrophilic copolymer may include a random or ordered block copolymer selected from the following: ABA block copolymer, BAB block copolymer, AB random alternating block copolymer, AB regularly alternating block copolymer and combinations thereof.
In one embodiment, the hydrophobic polymer is a silicone polymer. Thus, one or more layer(s) of the membrane system may comprise a blend formed from a silicone polymer with a hydrophobic-hydrophilic polymer. In one embodiment, the hydrophobic-hydrophilic polymer has a molecular weight of at least about 1000 g/mol, 5,000 g/mol, 8,000 g/mol, 10,000 g/mol, or 15,000 g/mol. In various embodiments, the molecular weight of any covalently continuous hydrophobic domain within the hydrophobic-hydrophilic polymer is at least about 500 g/mol, 700 g/mol, 1000 g/mol, 2000 g/mol, 5000 g/mol, or 8,000 g/mol. In various embodiments, the molecular weight of any covalently continuous hydrophilic domain within the hydrophobic-hydrophilic polymer is at least about 500 g/mol, 700 g/mol, 1000 g/mol, 2000 g/mol, 5000 g/mol, or 8,000 g/mol.
In various embodiments, the ratio of the silicone polymer to hydrophobic-hydrophilic polymer in a particular layer is selected to provide an amount of oxygen and water-soluble molecule solubility such that oxygen and water-soluble molecule transport through the layer is optimized according to the desired function of that particular layer. Furthermore, in some embodiments, the ratio of silicone polymer to hydrophobic-hydrophilic polymer as well as the polymeric compositions are selected such that a layer constructed from the material has interference characteristics that inhibit transport of one or more interfering species through the layer. Some known interfering species for a glucose sensor include, but are not limited to, acetaminophen, ascorbic acid, bilirubin, cholesterol, creatinine, dopamine, ephedrine, ibuprofen, L-dopa, methyl dopa, salicylate, tetracycline, tolazamide, tolbutamide, triglycerides, and uric acid. Accordingly, in some embodiments, a silicone polymer/hydrophobic-hydrophilic polymer layer as disclosed herein is less permeable to one or more of these interfering species than to the analyte, e.g., glucose.
In some embodiments, silicone polymer/hydrophobic-hydrophilic polymer blends are used in multiple layers of a membrane. In some of these embodiments, the ratio of silicone polymer to hydrophobic-hydrophilic polymer in the layers incorporating the blends varies according to the desired functionality of each layer. The relative amounts of silicone polymer and hydrophobic-hydrophilic polymer described below are based on the respective amounts found in the cured polymeric blend. Upon introduction into an aqueous environment, some of the polymeric components may leach out, thereby changing the relative amounts of silicone polymer and hydrophobic-hydrophilic polymer. For example, significant amounts of the portions of the hydrophobic-hydrophilic polymer that are not cross-linked may leach out.
In some embodiments, the amount of any cross-linking between the silicone polymer and the hydrophobic-hydrophilic polymer is substantially limited. In various embodiments, at least about 75%, 85%, 95%, or 99% of the silicone polymer is not covalently linked to the hydrophobic-hydrophilic polymer. In some embodiments, the silicone polymer and the hydrophobic-hydrophilic polymer do not cross link at all unless a cross-linking agent is used (e.g., such as described below). Similarly, in some embodiments, the amount of any entanglement (e.g., blending on a molecular level) between the silicone polymer and the hydrophobic-hydrophilic polymer is substantially limited. In one embodiment, the silicone polymer and hydrophobic-hydrophilic polymers form microdomains. For example, in one embodiment, the silicone polymer forms micellar structures surrounded by a network of hydrophobic-hydrophilic polymer.
The silicone polymer for use in the silicone/hydrophobic-hydrophilic polymer blend may be any suitable silicone polymer. In some embodiments, the silicone polymer is a liquid silicone rubber that may be vulcanized using a metal- (e.g., platinum), peroxide-, heat-, ultraviolet-, or other radiation-catalyzed process. In some embodiments, the silicone polymer is a dimethyl- and methylhydrogen-siloxane copolymer. In some embodiments, the copolymer has vinyl substituents. In some embodiments, commercially available silicone polymers may be used. For example, commercially available silicone polymer precursor compositions may be used to prepare the blends, such as described below. In one embodiment, MED-4840 available from NUSIL® Technology LLC is used as a precursor to the silicone polymer used in the blend. MED-4840 consists of a 2-part silicone elastomer precursor including vinyl-functionalized dimethyl- and methylhydrogen-siloxane copolymers, amorphous silica, a platinum catalyst, a crosslinker, and an inhibitor. The two components may be mixed together and heated to initiate vulcanization, thereby forming an elastomeric solid material. Other suitable silicone polymer precursor systems include, but are not limited to, MED-2174 peroxide-cured liquid silicone rubber available from NUSIL® Technology LLC, SILASTIC® MDX4-4210 platinum-cured biomedical grade elastomer available from DOW CORNING®, and Implant Grade Liquid Silicone Polymer (durometers 10-50) available from Applied Silicone Corporation.
The hydrophobic-hydrophilic polymer for use in the blend may be any suitable hydrophobic-hydrophilic polymer, including but not limited to components such as polyvinylpyrrolidone (PVP), polyhydroxyethyl methacrylate, polyvinylalcohol, polyacrylic acid, polyethers such as polyethylene glycol or polypropylene oxide, and copolymers thereof, including, for example, di-block, tri-block, alternating, random, comb, star, dendritic, and graft copolymers (block copolymers are discussed in U.S. Pat. Nos. 4,803,243 and 4,686,044, which are incorporated herein by reference). In one embodiment, the hydrophobic-hydrophilic polymer is a copolymer of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO). Suitable such polymers include, but are not limited to, PEO-PPO diblock copolymers, PPO-PEO-PPO triblock copolymers, PEO-PPO-PEO triblock copolymers, alternating block copolymers of PEO-PPO, random copolymers of ethylene oxide and propylene oxide, and blends thereof. In some embodiments, the copolymers may be optionally substituted with hydroxy substituents. Commercially available examples of PEO and PPO copolymers include the PLURONIC® brand of polymers available from BASF®. Some PLURONIC® polymers are triblock copolymers of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) having the general molecular structure:
- HO—(CH2CH2O)x—(CH2CH2CH2O)y—(CH2CH2O)x—OH
- where the repeat units x and y vary among various PLURONIC® products. The poly(ethylene oxide) blocks act as a hydrophilic domain allowing the dissolution of aqueous agents in the polymer. The poly(propylene oxide) block acts as a hydrophobic domain facilitating the blending of the PLURONIC® polymer with a silicone polymer. In one embodiment, PLURONIC® F-127 is used having x of approximately 100 and y of approximately 65. The molecular weight of PLURONIC® F-127 is approximately 12,600 g/mol as reported by the manufacture. Other PLURONIC® polymers include PPO-PEO-PPO triblock coplymers (e.g., PLURONIC® R products). Other suitable commercial polymers include, but are not limited to, SYNPERONICS® products available from UNIQEMA®.
The polyether structure of PLURONIC® polymers is relatively inert. Accordingly, without being bound by any particular theory, it is believed that the PLURONIC® polymers do not substantially react with the components in MED-4840 or other silicone polymer precursors.
Those of skill in the art will appreciate that other copolymers having hydrophilic and hydrophobic domains may be used. For example, in one alternative embodiment, a triblock copolymer having the structure hydrophobic-hydrophilic-hydrophobic may be used. In another alternative embodiment, a diblock copolymer having the structure hydrophilic-hydrophobic is used.
Synthesis of Silicone/Hydrophilic Polymer Blend Layers
Layers that include a silicone polymer-hydrophobic-hydrophilic polymer blend may be made using any of the methods of forming polymer blends known in the art. In one embodiment, a silicone polymer precursor (e.g., MED-4840) is mixed with a solution of a hydrophilic polymer (e.g., PLURONIC® F-127 dissolved in a suitable solvent such as acetone, ethyl alcohol, or 2-butanone). The mixture may then be drawn into a film or applied in a multi-layer membrane structure using any method known in the art (e.g., spraying, painting, dip coating , vapor depositing, molding, 3-D printing, lithographic techniques (e.g., photolithograph), micro- and nano-pipetting printing techniques, etc.). The mixture may then be cured under high temperature (e.g., 50-150° C.). Other suitable curing methods include ultraviolet or gamma radiation, for example. During curing, the silicone polymer precursor will vulcanize and the solvent will evaporate. In one embodiment, after the mixture is drawn into a film, another preformed layer of the membrane system is placed on the film. Curing of the film then provides bonding between the film and the other preformed layer. In one embodiment, the preformed layer is the cell disruptive layer. In one embodiment, the cell disruptive layer comprises a preformed porous silicone membrane. In other embodiments, the cell disruptive layer is also formed from a silicone polymer/hydrophobic-hydrophilic copolymer blend. In some embodiments, multiple films are applied on top of the preformed layer. Each film may posses a finite interface with adjacent films or may together form a physically continuous structure having a gradient in chemical composition.
Some amount of cross-linking agent may also be included in the mixture to induce cross-linking between hydrophobic-hydrophilic polymer molecules. For example, when using a PLURONIC® polymer, a cross-linking system that reacts with pendant or terminal hydroxy groups or methylene, ethylene, or propylene hydrogen atoms may be used to induce cross linking. Non-limiting examples of suitable cross-linking agents include ethylene glycol diglycidyl ether (EGDE), poly(ethylene glycol) diglycidyl ether (PEGDE), or dicumyl peroxide (DCP). While not being bound by any particular theory, at low concentrations, these cross-linking agents are believed to react primarily with the PLURONIC® polymer with some amount possibly inducing cross-linking in the silicone polymer or between the PLURONIC® polymer and the silicone polymer. In one embodiment, enough cross-linking agent is added such that the ratio of cross-linking agent molecules to hydrophobic-hydrophilic polymer molecules added when synthesizing the blend is about 10 to about 30 (e.g., about 15 to about 20). In one embodiment, from about 0.5% to about 15% w/w of cross-linking agent is added relative to the total dry weights of cross-linking agent, silicone polymer, and hydrophobic-hydrophilic polymer added when blending the ingredients (in one example, about 1% to about 10%). In one embodiment, from about 1% to about 15% of the dry ingredient weight is the PLURONIC® polymer. During the curing process, substantially all of the cross-linking agent is believed to react, leaving substantially no detectable unreacted cross-linking agent in the final film.
In some embodiments, other agents may be added to the mixture to facilitate formation of the blend. For example, a small amount of butylhydroxy toluene (BHT) (e.g., about 0.01% w/w) or other suitable antioxidant may be mixed with a PLURONIC® to stabilize it.
In some alternative embodiments, precursors of both the silicone polymer and hydrophobic-hydrophilic polymer may be mixed prior to curing such that polymerization of both the silicone polymer and the hydrophobic-hydrophilic polymer occur during curing. In another embodiment, already polymerized silicone polymer is mixed with a hydrophobic-hydrophilic polymer such that no significant polymerization occurs during curing.
Cell Disruptive Domain
The cell disruptive layer 40 is positioned most distal to the implantable device and is designed to support tissue ingrowth, to disrupt contractile forces typically found in a foreign body capsule, to encourage vascularity within the membrane, and/or to disrupt the formation of a barrier cell layer. In one embodiment, the cell disruptive layer 40 has an open-celled configuration with interconnected cavities and solid portions, wherein the distribution of the solid portion and cavities of the cell disruptive layer includes a substantially co-continuous solid domain and includes more than one cavity in three dimensions substantially throughout the entirety of the first domain. Cells can enter into the cavities; however they cannot travel through or wholly exist within the solid portions. The cavities allow most substances to pass through, including, for example, cells, and molecules. U.S. Pat. No. 6,702,857, filed Jul. 27, 2001, and entitled “MEMBRANE FOR USE WITH IMPLANTABLE DEVICES” and U.S. patent application Ser. No. 10/647,065, filed Aug. 22, 2003, published in U.S. Publication No. 2005-0112169 A1 and entitled, “POROUS MEMBRANES FOR USE WITH IMPLANTABLE DEVICES” describe membranes having a cell disruptive domain and are both incorporated herein by reference in their entirety.
The cell disruptive layer 40 is preferably formed from high oxygen soluble materials such as polymers formed from silicone, fluorocarbons, perfluorocarbons, or the like. In these embodiments, transport of water-soluble agents such as an aqueous analyte occurs primarily through the pores and cavities of the layer. In some embodiments, the cell disruptive domain is formed from polyethylene-co-tetrafluoroethylene, polyolefin, polyester, polycarbonate, biostable polytetrafluoroethylene, homopolymers, copolymers, terpolymers of polytetrafluoroethylene, polyurethanes, polypropylene (PP), polyvinylchloride (PVC), polyvinylidene fluoride (PVDF), polybutylene terephthalate (PBT), polymethylmethacrylate (PMMA), polyether ether ketone (PEEK), polyurethanes, cellulosic polymers, polysulfones or block copolymers thereof including, for example, di-block, tri-block, alternating, random and graft copolymers. In other embodiments, the cell disruptive layer is formed from a silicone composition with a non-silicon containing hydrophile such as such as polyethylene glycol, propylene glycol, pyrrolidone, esters, amides, or carbonates covalently incorporated or grafted therein such that water-soluble agents can also be transported through polymeric matrix of the cell disruptive layer 40. Such compositions are described for example in U.S. application Ser. No. 10/695,636, filed Oct. 28, 2003, published in Publication No. 2005/0090607 and entitled “SILICONE COMPOSITION FOR BIOCOMPATIBLE MEMBRANE,” which is incorporated herein by reference in its entirety. In still other embodiments, the cell disruptive layer is formed from a monomer, polymer, copolymer, or blend including one or more of: lactic acid, glycolic acid, anhydrides, phospazenes, vinyl alcohol, ethylene vinyl alcohol, acetates, ε-caprolactone, β-hydroxybutyrate, γ-ethyl glutamate, DTH iminocarbonate, Bisphenol A iminocarbonate, sebacic acid, hexadecanoic acid, saccharides, chitosan, hydyoxyethyl methacrylate (HEMA), ceramics, hyaluronic acid (HA), collagen, gelatin, starches, hydroxy apatite, calcium phosphates, bioglasses, amino acid sequences, proteins, glycoproteins, protein fragments, agarose, fibrin, n-butylene, isobutylene, dioxanone, nylons, vinyl chlorides, amides, ethylenes, n-butyl methacrylate (BMA), metal matrix composites (MMCs), metal oxides (e.g. aluminum), DETOSU-1,6 HD-t-CDM ortho ester, styrene, and plasma treated surfaces of any of the above.
In some embodiments, the cell disruptive layer 40 is formed from silicone polymer/hydrophobic-hydrophilic polymer blends such as described above. Due to the open-cell configuration of the cell disruptive layer 40, the ratio of silicone polymer to hydrophobic-hydrophilic polymer may be chosen to increase the structural integrity of the layer so that the open-cell configuration is maintained. Alternatively, the structural integrity of the cell disruptive layer can be increased by choosing a silicone polymer having properties suitable for increasing structural integrity (e.g., a silicone polymer having an increased durometer). In one embodiment, the concentration of hydrophobic-hydrophilic polymer (e.g., PLURONIC® F-127) relative to silicone polymer (e.g., MED-4840) is from about 1% to about 30%, preferably from about 5% to about 20% in the cell disruptive layer 40.
In preferred embodiments, the thickness of the cell disruptive domain is from about 10 or less, 20, 30, 40, 50, 60, 70, 80, or 90 microns to about 1500, 2000, 2500, or 3000 or more microns. In more preferred embodiments, the thickness of the cell disruptive domain is from about 100, 150, 200 or 250 microns to about 1000, 1100, 1200, 1300, or 1400 microns. In even more preferred embodiments, the thickness of the cell disruptive domain is from about 300, 350, 400, 450, 500, or 550 microns to about 500, 550, 600, 650, 700, 750, 800, 850, or 900 microns.
The cell disruptive domain is optional and can be omitted when using an implantable device that does not prefer tissue ingrowth, for example, a short-lived device (for example, less than one day to about a week or up to about one month) or one that delivers tissue response modifiers.
Bioprotective Layer
The bioprotective layer 42 is positioned less distal to the implantable device than the cell disruptive layer, and can be resistant to cellular attachment, impermeable to cells, and/or is composed of a biostable material. When the bioprotective layer is resistant to cellular attachment (for example, attachment by inflammatory cells, such as macrophages, which are therefore kept a sufficient distance from other domains, for example, the enzyme domain), hypochlorite and other oxidizing species are short-lived chemical species in vivo, and biodegradation does not occur. Additionally, the materials preferred for forming the bioprotective layer 42 may be resistant to the effects of these oxidative species and have thus been termed biodurable. See, for example, U.S. Pat. No. 6,702,857, filed Jul. 27, 2001, and entitled “MEMBRANE FOR USE WITH IMPLANTABLE DEVICES” and U.S. patent application Ser. No. 10/647,065, filed Aug. 22, 2003, published in Publication No. 20050112169 and entitled, “POROUS MEMBRANES FOR USE WITH IMPLANTABLE DEVICES,” both of which are incorporated herein by reference in their entirety.
In one embodiment, bioprotective layer 42 is formed from high oxygen soluble materials such as polymers formed from silicone, fluorocarbons, perfluorocarbons, or the like. In one embodiment, the cell impermeable domain is formed from a silicone composition with a hydrophile such as such as polyethylene glycol, propylene glycol, pyrrolidone, esters, amides, carbonates, or polypropylene glycol covalently incorporated or grafted therein. In still other embodiments, the bioprotective layer is formed from a monomer, polymer, copolymer, or blend including one or more of: lactic acid, glycolic acid, anhydrides, phospazenes, vinyl alcohol, ethylene vinyl alcohol, acetates, ε-caprolactone, β-hydroxybutyrate, γ-ethyl glutamate, DTH iminocarbonate, Bisphenol A iminocarbonate, sebacic acid, hexadecanoic acid, saccharides, chitosan, hydyoxyethyl methacrylate (HEMA), ceramics, hyaluronic acid (HA), collagen, gelatin, starches, hydroxy apatite, calcium phosphates, bioglasses, amino acid sequences, proteins, glycoproteins, protein fragments, agarose, fibrin, n-butylene, isobutylene, dioxanone, nylons, vinyl chlorides, amides, ethylenes, n-butyl methacrylate (BMA), metal matrix composites (MMCs), metal oxides (e.g. aluminum), DETOSU-1,6 HD-t-CDM ortho ester, styrene, and plasma treated surfaces of any of the above.
In one preferred embodiment, the bioprotective layer 42 is formed from silicone polymer/hydrophobic-hydrophilic polymer blends such as described above. It is advantageous that the cell impermeable layer 42 have both high oxygen and aqueous analyte solubility so that sufficient reactants reach the enzyme layer. Accordingly, in one embodiment, the concentration of hydrophobic-hydrophilic polymer (e.g., PLURONIC® F-127) relative to silicone polymer (e.g., MED-4840) is relatively high, e.g., from about 10% to about 30% in the bioprotective layer 42. In one embodiment, the concentration of hydrophobic-hydrophilic polymer is from about 15% to about 25% (e.g., about 20%).
In preferred embodiments, the thickness of the bioprotective layer is from about 10 or 15 microns or less to about 125, 150, 175, 200 or 250 microns or more. In more preferred embodiments, the thickness of the bioprotective layer is from about 20, 25, 30, or 35 microns to about 60, 65, 70, 75, 80, 85, 90, 95, or 100 microns. In even more preferred embodiments, the bioprotective layer is from about 20 or 25 microns to about 50, 55, or 60 microns thick.
The cell disruptive layer 40 and bioprotective layer 42 of the membrane system can be formed together as one unitary structure. Alternatively, the cell disruptive and bioprotective layers 40, 42 of the membrane system can be formed as two layers mechanically or chemically bonded together. In one embodiment, the cell disruptive layer 40 and bioprotective layer 42 consist of a unitary structure having graduated properties. For example, the porosity of the unitary structure may vary from high porosity at the tissue side of the layer to very low or no porosity at the sensor side. In addition, the chemical properties of such a graduated structure may also vary. For example, the concentration of the hydrophobic-hydrophilic polymer may vary throughout the structure, increasing in concentration toward the sensor side of the layer. The lower concentration on the tissue side allows for increased structural integrity to support an open-celled structure while the higher concentration on the sensor side promotes increased transport of aqueous analytes through the polymer blend.
Diffusion Resistance Layer
The diffusion resistance layer 44 or 150 is situated more proximal to the implantable device relative to the cell disruptive layer. The diffusion resistance layer controls the flux of oxygen and other analytes (for example, glucose) to the underlying enzyme domain. As described in more detail elsewhere herein, there exists a molar excess of glucose relative to the amount of oxygen in blood; that is, for every free oxygen molecule in extracellular fluid, there are typically more than 100 glucose molecules present (see Updike et al., Diabetes Care 5:207-21(1982)). However, an immobilized enzyme-based sensor employing oxygen as cofactor is supplied with oxygen in non-rate-limiting excess in order to respond linearly to changes in glucose concentration, while not responding to changes in oxygen tension. More specifically, when a glucose-monitoring reaction is oxygen-limited, linearity is not achieved above minimal concentrations of glucose. Without a semipermeable membrane situated over the enzyme domain to control the flux of glucose and oxygen, a linear response to glucose levels can be obtained only up to about 40 mg/dL. However, in a clinical setting, a linear response to glucose levels is desirable up to at least about 500 mg/dL.
The diffusion resistance layer 44 or 150 includes a semipermeable membrane that controls the flux of oxygen and glucose to the underlying enzyme layer 46 or 147, preferably rendering oxygen in non-rate-limiting excess. As a result, the upper limit of linearity of glucose measurement is extended to a much higher value than that which is achieved without the diffusion resistance layer. In one embodiment, the diffusion resistance layer 44 or 150 exhibits an oxygen-to-glucose permeability ratio of approximately 200:1. As a result, one-dimensional reactant diffusion is adequate to provide excess oxygen at all reasonable glucose and oxygen concentrations found in the subcutaneous matrix (See Rhodes et al., Anal. Chem., 66:1520-1529 (1994)). In some embodiments, a lower ratio of oxygen-to-glucose can be sufficient to provide excess oxygen by using a high oxygen soluble domain (for example, a silicone material) to enhance the supply/transport of oxygen to the enzyme membrane and/or electroactive surfaces. By enhancing the oxygen supply through the use of a silicone composition, for example, glucose concentration can be less of a limiting factor. In other words, if more oxygen is supplied to the enzyme and/or electroactive surfaces, then more glucose can also be supplied to the enzyme without creating an oxygen rate-limiting excess.
In one embodiment, the diffusion resistance layer 44 or 150 is preferably formed from high oxygen soluble materials such as polymers formed from silicone, fluorocarbons, perfluorocarbons, or the like. In one embodiment, the resistance domain is formed from a silicone composition with a hydrophile such as such as polyethylene glycol, propylene glycol, pyrrolidone, esters, amides, carbonates, or polypropylene glycol covalently incorporated or grafted therein. In some alternative embodiments, the diffusion resistance layer is formed from polyurethane, for example, a polyurethane urea/polyurethane-block-polyethylene glycol blend. In still other embodiments, the diffusion resistance layer is formed from a monomer, polymer, copolymer, or blend including one or more of: lactic acid, glycolic acid, anhydrides, phospazenes, vinyl alcohol, ethylene vinyl alcohol, acetates, ε-caprolactone, β-hydroxybutyrate, γ-ethyl glutamate, DTH iminocarbonate, Bisphenol A iminocarbonate, sebacic acid, hexadecanoic acid, saccharides, chitosan, hydyoxyethyl methacrylate (HEMA), ceramics, hyaluronic acid (HA), collagen, gelatin, starches, hydroxy apatite, calcium phosphates, bioglasses, amino acid sequences, proteins, glycoproteins, protein fragments, agarose, fibrin, n-butylene, isobutylene, dioxanone, nylons, vinyl chlorides, amides, ethylenes, n-butyl methacrylate (BMA), metal matrix composites (MMCs), metal oxides (e.g. aluminum), DETOSU-1,6 HD-t-CDM ortho ester, styrene, and plasma treated surfaces of any of the above.
In some preferred embodiments, the diffusion resistance layer 44 or 150 is formed from silicone polymer/hydrophobic-hydrophilic polymer blends such as described above. In some alternative embodiments, the diffusion resistance layer 44 or 150 is formed from silicone polymer/hydrophilic polymer blends. In order to restrict the transport of an aqueous analyte such as glucose, lower concentrations of hydrophilic polymer can be employed. Accordingly, in one embodiment, the concentration of hydrophobic-hydrophilic polymer (e.g., PLURONIC® F-127) relative to silicone polymer (e.g., MED-4840) is from about 1% to about 15% in the diffusion resistance layer 44 (e.g., from about 6% to about 10%).
In some alternative embodiments, the diffusion resistance layer includes a polyurethane membrane with both hydrophilic and hydrophobic regions to control the diffusion of glucose and oxygen to an analyte sensor, the membrane being fabricated easily and reproducibly from commercially available materials. A suitable hydrophobic polymer component is a polyurethane, or polyetherurethaneurea. Polyurethane is a polymer produced by the condensation reaction of a diisocyanate and a difunctional hydroxyl-containing material. A polyurethaneurea is a polymer produced by the condensation reaction of a diisocyanate and a difunctional amine-containing material. Preferred diisocyanates include aliphatic diisocyanates containing from about 4 to about 8 methylene units. Diisocyanates containing cycloaliphatic moieties can also be useful in the preparation of the polymer and copolymer components of the membranes of preferred embodiments. The material that forms the basis of the hydrophobic matrix of the diffusion resistance layer can be any of those known in the art as appropriate for use as membranes in sensor devices and as having sufficient permeability to allow relevant compounds to pass through it, for example, to allow an oxygen molecule to pass through the membrane from the sample under examination in order to reach the active enzyme or electrochemical electrodes. Examples of materials which can be used to make non-polyurethane type membranes include vinyl polymers, polyethers, polyesters, polyamides, inorganic polymers such as polysiloxanes and polycarbosiloxanes, natural polymers such as cellulosic and protein based materials, and mixtures or combinations thereof.
In one embodiment, the hydrophilic polymer component is polyethylene oxide. For example, one useful hydrophobic-hydrophilic copolymer component is a polyurethane polymer that includes about 20% hydrophilic polyethylene oxide. The polyethylene oxide portions of the copolymer are thermodynamically driven to separate from the hydrophobic portions of the copolymer and the hydrophobic polymer component. The 20% polyethylene oxide-based soft segment portion of the copolymer used to form the final blend affects the water pick-up and subsequent glucose permeability of the membrane.
In some embodiments, the diffusion resistance layer 44 or 150 can be formed as a unitary structure with the bioprotective layer 42; that is, the inherent properties of the diffusion resistance layer 44 or 150 can provide the functionality described with reference to the bioprotective layer 42 such that the bioprotective layer 42 is incorporated as a part of diffusion resistance layer 44 or 150. In these embodiments, the combined diffusion resistance layer/bioprotective layer can be bonded to or formed as a skin on the cell disruptive layer 40. As discussed above, the diffusion resistance layer/bioprotective layer may also be part of a unitary structure with the cell disruptive layer 40 such that the outer layer of the membrane system is graduated to the interface with the enzyme layer. In another embodiment, the diffusion resistance layer/bioprotective layer may also be part of a unitary structure with the cell disruptive layer 40 including a chemical gradient with transition properties between the outer layer and the enzyme layer. In another embodiment, the diffusion resistance layer 44 or 150 is formed as a distinct layer and chemically or mechanically bonded to the cell disruptive layer 40 (if applicable) or the bioprotective layer 42 (when the resistance domain is distinct from the cell impermeable domain).
In still another embodiment, the diffusion resistance layer may be a distinct layer from the cell disruptive layer or the bioprotective layer but may nonetheless include a chemical gradient such that its diffusion resistance property transitions from one side of the layer to the other. Similarly, the cell disruptive layer and bioprotective layers may also include a chemical gradient. Where multiple such layers have chemical gradients, the chemical compositions at the interface between two layers may be identical or different.
In preferred embodiments, the thickness of the resistance domain is from about 0.05 microns or less to about 200 microns or more. In more preferred embodiments, the thickness of the resistance domain is from about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 10, 15, 20, 25, 30, or 35 microns to about, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 19.5, 20, 30, 40, 50, 60, 70, 75, 80, 85, 90, 95, or 100 microns. In more preferred embodiments, the thickness of the resistance domain is from about 2, 2.5 or 3 microns to about 3.5, 4, 4.5, or 5 microns in the case of a transcutaneously implanted sensor or from about 20 or 25 microns to about 40 or 50 microns in the case of a wholly implanted sensor.
Enzyme Layer
An immobilized enzyme layer 46 or 149 is situated less distal from the electrochemically reactive surfaces than the diffusion resistance layer 44 or 150. In one embodiment, the immobilized enzyme layer 46 or 149 comprises glucose oxidase. In other embodiments, the immobilized enzyme layer 46 or 149 can be impregnated with other oxidases, for example, galactose oxidase, cholesterol oxidase, amino acid oxidase, alcohol oxidase, lactate oxidase, or uricase. For example, for an enzyme-based electrochemical glucose sensor to perform well, the sensor'"'"'s response should neither be limited by enzyme activity nor cofactor concentration.
The enzyme layer 44 or 149 is preferably formed from high oxygen soluble materials such as polymers formed from silicone, fluorocarbons, perfluorocarbons, or the like. In one embodiment, the enzyme domain is formed from a silicone composition with a hydrophile such as such as polyethylene glycol, propylene glycol, pyrrolidone, esters, amides, carbonates, or polypropylene glycol covalently incorporated or grafted therein. In one embodiment, the enzyme layer 44 or 149 is formed from polyurethane.
In one embodiment, high oxygen solubility within the enzyme layer can be achieved by using a polymer matrix to host the enzyme within the enzyme layer that has a high solubility of oxygen. In one exemplary embodiment of fluorocarbon-based polymers, the solubility of oxygen within a perfluorocarbon-based polymer is 50-volume %. As a reference, the solubility of oxygen in water is approximately 2-volume %.
In one preferred embodiment, the enzyme layer is formed from silicone polymer/hydrophobic-hydrophilic polymer blends such as described above. In one embodiment, the concentration of hydrophobic-hydrophilic polymer (e.g., PLURONIC® F-127) relative to silicone polymer (e.g., MED-4840) is relatively high, e.g., from about 10% to about 30% in the bioprotective layer 42. In one embodiment, the concentration of hydrophobic-hydrophilic polymer is from about 15% to about 25% (e.g., about 20%).
Utilization of a high oxygen solubility material for the enzyme layer is advantageous because the oxygen dissolves more readily within the layer and thereby acts as a high oxygen soluble domain optimizing oxygen availability to oxygen-utilizing sources (for example, the enzyme and/or counter electrode). When the diffusion resistance layer 44 or 149 and enzyme layer 46 or 150 both comprise a high oxygen soluble material, the chemical bond between the enzyme layer 46 or 150 and diffusion resistance layer 44 or 149 can be optimized, and the manufacturing made easy.
In some alternative embodiments, the enzyme domain is constructed of aqueous dispersions of colloidal polyurethane polymers including the enzyme.
In preferred embodiments, the thickness of the enzyme domain is from about 0.05 micron or less to about 20, 30 40, 50, 60, 70, 80, 90, or 100 microns or more. In more preferred embodiments, the thickness of the enzyme domain is between about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, 4, or 5 microns and 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 19.5, 20, 25, or 30 microns. In even more preferred embodiments, the thickness of the enzyme domain is from about 2, 2.5, or 3 microns to about 3.5, 4, 4.5, or 5 microns in the case of a transcutaneously implanted sensor or from about 6, 7, or 8 microns to about 9, 10, 11, or 12 microns in the case of a wholly implanted sensor.
Interference Layer
The interference layer 48 or 148 is situated less distal to the implantable device than the immobilized enzyme layer. Interferants are molecules or other species that are electro-reduced or electro-oxidized at the electrochemically reactive surfaces, either directly or via an electron transfer agent, to produce a false signal (for example, urate, ascorbate, or acetaminophen). In one embodiment, the interference layer 48 or 148 prevents the penetration of one or more interferants into the electrolyte phase around the electrochemically reactive surfaces. Preferably, this type of interference layer is much less permeable to one or more of the interferants than to the analyte.
In one embodiment, the interference domain 48 or 148 can include ionic components incorporated into a polymeric matrix to reduce the permeability of the interference layer to ionic interferants having the same charge as the ionic components. In another embodiment, the interference layer 48 or 148 includes a catalyst (for example, peroxidase) for catalyzing a reaction that removes interferants. U.S. Pat. No. 6,413,396 and U.S. Pat. No. 6,565,509 disclose methods and materials for eliminating interfering species, both of which are incorporated herein by reference in their entirety; however in the preferred embodiments any suitable method or material can be employed.
In another embodiment, the interference layer 48 or 148 includes a thin membrane that is designed to limit diffusion of species, for example, those greater than 34 kD in molecular weight, for example. The interference layer permits analytes and other substances (for example, hydrogen peroxide) that are to be measured by the electrodes to pass through, while preventing passage of other substances, such as potentially interfering substances. In one embodiment, the interference layer 48 or 148 is constructed of polyurethane. In an alternative embodiment, the interference layer 48 or 148 comprises a high oxygen soluble polymer.
In one embodiment, the interference layer 48 or 148 is formed from silicone polymer/hydrophobic-hydrophilic polymer blends such as described above. As described herein, such polymer blends can have the characteristics of limiting transport of one or more interferants therethrough. Because of this property, the use of the polymer blends in a membrane layer other than the interference layer may also confer interferant resistance properties in those layers, potentially eliminating the need for a separate interference layer. In some embodiments, these layers allow diffusion of glucose therethrough but limit diffusion of one or more interferant therethrough.
In some embodiments, the interference layer 48 or 148 is formed from one or more cellulosic derivatives. In general, cellulosic derivatives include polymers such as cellulose acetate, cellulose acetate butyrate, 2-hydroxyethyl cellulose, cellulose acetate phthalate, cellulose acetate propionate, cellulose acetate trimellitate, and the like.
In one preferred embodiment, the interference layer 48 or 148 is formed from cellulose acetate butyrate. Cellulose acetate butyrate with a molecular weight of about 10,000 daltons to about 75,000 daltons, preferably from about 15,000, 20,000, or 25,000 daltons to about 50,000, 55,000, 60,000, 65,000, or 70,000 daltons, and more preferably about 20,000 daltons is employed. In certain embodiments, however, higher or lower molecular weights can be preferred. Additionally, a casting solution or dispersion of cellulose acetate butyrate at a weight percent of about 15% to about 25%, preferably from about 15%, 16%, 17%, 18%, 19% to about 20%, 21%, 22%, 23%, 24% or 25%, and more preferably about 18% is preferred. Preferably, the casting solution includes a solvent or solvent system, for example an acetone:ethanol solvent system. Higher or lower concentrations can be preferred in certain embodiments. A plurality of layers of cellulose acetate butyrate can be advantageously combined to form the interference domain in some embodiments, for example, three layers can be employed. It can be desirable to employ a mixture of cellulose acetate butyrate components with different molecular weights in a single solution, or to deposit multiple layers of cellulose acetate butyrate from different solutions comprising cellulose acetate butyrate of different molecular weights, different concentrations, and/or different chemistries (e.g., functional groups). It can also be desirable to include additional substances in the casting solutions or dispersions, e.g., functionalizing agents, crosslinking agents, other polymeric substances, substances capable of modifying the hydrophilicity/hydrophobicity of the resulting layer, and the like.
In one alternative embodiment, the interference layer 48 or 148 is formed from cellulose acetate. Cellulose acetate with a molecular weight of about 30,000 daltons or less to about 100,000 daltons or more, preferably from about 35,000, 40,000, or 45,000 daltons to about 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000, 90,000, or 95,000 daltons, and more preferably about 50,000 daltons is preferred. Additionally, a casting solution or dispersion of cellulose acetate at a weight percent of about 3% to about 10%, preferably from about 3.5%, 4.0%, 4.5%, 5.0%, 5.5%, 6.0%, or 6.5% to about 7.5%, 8.0%, 8.5%, 9.0%, or 9.5%, and more preferably about 8% is preferred. In certain embodiments, however, higher or lower molecular weights and/or cellulose acetate weight percentages can be preferred. It can be desirable to employ a mixture of cellulose acetates with molecular weights in a single solution, or to deposit multiple layers of cellulose acetate from different solutions comprising cellulose acetates of different molecular weights, different concentrations, or different chemistries (e.g., functional groups). It can also be desirable to include additional substances in the casting solutions or dispersions such as described in more detail above.
Layer(s) prepared from combinations of cellulose acetate and cellulose acetate butyrate, or combinations of layer(s) of cellulose acetate and layer(s) of cellulose acetate butyrate can also be employed to form the interference layer 48 or 148.
In some alternative embodiments, additional polymers, such as Nafion®, can be used in combination with cellulosic derivatives to provide.equivalent and/or enhanced function of the interference layer 48 or 148. As one example, a 5 wt % Nafion® casting solution or dispersion can be used in combination with a 8 wt % cellulose acetate casting solution or dispersion, e.g., by dip coating at least one layer of cellulose acetate and subsequently dip coating at least one layer Nafion® onto a needle-type sensor such as described with reference to the preferred embodiments. Any number of coatings or layers formed in any order may be suitable for forming the interference domain of the preferred embodiments.
In some alternative embodiments, more than one cellulosic derivative can be used to form the interference layer 48 or 148 of the preferred embodiments. In general, the formation of the interference domain on a surface utilizes a solvent or solvent system in order to solvate the cellulosic derivative (or other polymer) prior to film formation thereon. In preferred embodiments, acetone and ethanol are used as solvents for cellulose acetate; however one skilled in the art appreciates the numerous solvents that are suitable for use with cellulosic derivatives (and other polymers). Additionally, one skilled in the art appreciates that the preferred relative amounts of solvent can be dependent upon the cellulosic derivative (or other polymer) used, its molecular weight, its method of deposition, its desired thickness, and the like. However, a percent solute of from about 1% to about 25% is preferably used to form the interference domain solution so as to yield an interference layer 48 or 148 having the desired properties. The cellulosic derivative (or other polymer) used, its molecular weight, method of deposition, and desired thickness can be adjusted, depending upon one or more other of the parameters, and can be varied accordingly as is appreciated by one skilled in the art.
In some alternative embodiments, other polymer types that can be utilized as a base material for the interference layer 48 or 148 include polyurethanes, polymers having pendant ionic groups, and polymers having controlled pore size, for example. In one such alternative embodiment, the interference domain includes a thin, hydrophobic membrane that is non-swellable and restricts diffusion of low molecular weight species. The interference layer 48 or 148 is permeable to relatively low molecular weight substances, such as hydrogen peroxide, but restricts the passage of higher molecular weight substances, including glucose and ascorbic acid. Other systems and methods for reducing or eliminating interference species that can be applied to the membrane system of the preferred embodiments are described in co-pending U.S. patent application Ser. No. 10/896,312 filed Jul. 21, 2004 and entitled “ELECTRODE SYSTEMS FOR ELECTROCHEMICAL SENSORS,” Ser. No. 10/991,353, filed Nov. 16, 2004 and entitled, “AFFINITY DOMAIN FOR AN ANALYTE SENSOR,” Ser. No. 11/007,635, filed Dec. 7, 2004 and entitled “SYSTEMS AND METHODS FOR IMPROVING ELECTROCHEMICAL ANALYTE SENSORS” and Ser. No. 11/004,561, filed Dec. 3, 2004 and entitled, “CALIBRATION TECHNIQUES FOR A CONTINUOUS ANALYTE SENSOR.”
In preferred embodiments, the thickness of the interference domain is from about 0.05 microns or less to about 20 microns or more. In more preferred embodiments, the thickness of the interference domain is between about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, or 3.5 microns and about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 19.5 microns. In more preferred embodiments, the thickness of the interference domain is from about 0.6, 0.7, 0.8, 0.9, or 1 micron to about 2, 3, or 4 microns.
Electrode Layer
An electrode layer 50 or 147 is situated more proximal to the electrochemically reactive surfaces than the interference layer 48 or 148. To ensure the electrochemical reaction, the electrode layer 50 or 147 includes a semipermeable coating that maintains hydrophilicity at the electrochemically reactive surfaces of the sensor interface. The electrode layer 50 or 147 enhances the stability of the interference layer 48 or 148 by protecting and supporting the material that makes up the interference layer. The electrode layer 50 or 147 also assists in stabilizing the operation of the device by overcoming electrode start-up problems and drifting problems caused by inadequate electrolyte. The buffered electrolyte solution contained in the electrode layer also protects against pH-mediated damage that can result from the formation of a large pH gradient between the substantially hydrophobic interference domain and the electrodes due to the electrochemical activity of the electrodes. In some embodiments, the electrode layer may not be used, for example, when an interference layer is not provided.
In one embodiment, the electrode layer 50 or 147 includes a flexible, water-swellable, substantially solid gel-like film (e.g., a hydrogel) having a “dry film” thickness of from about 0.05 microns to about 100 microns, more preferably from about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, or 3.5, 4, 4.5, 5, or 5.5 to about 5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 13, 14, 15, 16, 17, 18, 19, 19.5, 20, 30, 40, 50, 60, 70, 80, 90, or 100 microns. In even more preferred embodiments, the thickness of the electrolyte domain is from about 2, 2.5 or 3 microns to about 3.5, 4, 4.5, or 5 microns in the case of a transcutaneously implanted sensor or from about 6, 7, or 8 microns to about 9, 10, 11, or 12 microns in the case of a wholly implanted sensor. “Dry film” thickness refers to the thickness of a cured film cast from a coating formulation onto the surface of the membrane by standard coating techniques.
In some embodiments, the electrode layer 50 or 147 is formed of a curable mixture of a urethane polymer and a hydrophilic polymer. Particularly preferred coatings are formed of a polyurethane polymer having anionic carboxylate functional groups and non-ionic hydrophilic polyether segments, which is crosslinked in the presence of polyvinylpyrrolidone and cured at a moderate temperature of about 50° C. In some preferred embodiments, the electrode layer 50 or 147 is formed from high oxygen soluble materials such as polymers formed from silicone, fluorocarbons, perfluorocarbons, or the like. In one preferred embodiment, the electrode layer 50 or 147 is formed from silicone polymer/hydrophobic-hydrophilic polymer blends such as described above.
Underlying the electrode layer is an electrolyte phase is a free-fluid phase including a solution containing at least one compound, typically a soluble chloride salt, which conducts electric current. In one embodiment wherein the membrane system is used with a glucose sensor such as is described herein, the electrolyte phase flows over the electrodes and is in contact with the electrolyte layer. The devices of the preferred embodiments contemplate the use of any suitable electrolyte solution, including standard, commercially available solutions. Generally, the electrolyte phase can have the same osmotic pressure or a lower osmotic pressure than the sample being analyzed. In preferred embodiments, the electrolyte phase comprises normal saline.
In various embodiments, any of the layers discussed above can be omitted, altered, substituted for, and/or incorporated together. For example, a distinct bioprotective layer may not exist. In such embodiments, other domains accomplish the function of the bioprotective layer. As another example, the interference layer can be eliminated in certain embodiments wherein two-electrode differential measurements are employed to eliminate interference, for example, one electrode being sensitive to glucose and electrooxidizable interferants and the other only to interferants, such as is described in U.S. Pat. No. 6,514,718, which is incorporated herein by reference in its entirety. In such embodiments, the interference layer can be omitted.
In one embodiment, the membrane system 18 comprises only two layers. One layer is the enzyme layer as described above. The second layer is positioned more distal than the enzyme layer and serves one or more of the functions described above for the cell disruptive layer, bioprotective layer, and diffusion resistance layer. In one embodiment, this second layer is graduated either structurally and/or chemically as describe above such that different domains of the second layer serve different functions such as cell disruption, bio-protection, or diffusion resistance. In one embodiment, both layers of this membrane system are formed from silicone polymer/hydrophobic-hydrophilic polymer blends such as described above.
In one embodiment, every layer in the membrane system 18 is formed from silicone polymer/hydrophobic-hydrophilic polymer blends such as described above. Such uniformity in ingredients allows for ease of manufacturing while at the same time allowing for tailoring of properties by varying the ratio of silicone polymer to hydrophilic polymer.
A coating solution is prepared by placing approximately 281 gm of dimethylacetamide (DMAC) into a 3 L stainless steel bowl to which a solution of a co-polymer of polyetherurethaneurea with PEG (344 gm of Chronothane H (Cardiotech International, Inc., Woburn, Mass.), 29,750 cp @ 25% solids in DMAC) is added. To this mixture is added a polyurethaneurea (approximately 312 gm, Chronothane 1020 (Cardiotech International, Inc., Woburn, Mass.), 6275 cp @ 25% solids in DMAC). The bowl is then fitted to a planetary mixer with a paddle-type blade and the contents are stirred for 30 minutes at room temperature. Coatings solutions prepared in this manner are then coated at between room temperature to about 70° C. onto a PET release liner (Douglas Hansen Co., Inc., Minneapolis, Minn.) using a knife-over-roll set at a 0.012 inch gap. The film is continuously dried at 120° C. to about 150° C. The final film thickness is approximately 0.0015 inches.
30 g of PLURONIC® F-127 (PF-127) was dissolved under stirring in 100 g of anhydrous acetone at 40° C. 13 g of acetone was added to 37.3 g of the PF-127 solution followed by adding 4.8 g of dicumyl peroxide (DCP). 40 g of MED-4840 was mixed in a speed mixer at a speed of 3300 rpm for 60 seconds. The MED-4840 mixture was then placed in a motorized mechanical mixer equipped with a spiral dough hook. The mixture was stirred at low speed for 30 s. The stirring speed was then increased to medium-low and the PF-127/DCP solution was added at a rate of 3.5-4.0 g every 30 seconds. After all of the PF-127/DCP solution was added, the mixture was stirred at medium speed for 3 minutes. The mixture was then placed in a Speed Mixer and mixed at 3300 rpm for 60 seconds. This process was repeated until the desired viscosity was reached.
5-10 mL of the mixture was placed in an evenly-distributed line between the arms of the drawdown blade on a drawdown machine. The drawdown machine was used to create a 9 inch long and 0.0045 inch thick film at a speed of about 0.7 inches/minute. A preformed piece of porous silicone (to act as a cell disruptive layer) was placed skin side down on the drawn film and tapped lightly to promote the polymeric mixture to penetrate into the pores of the porous silicone. The film was then cured for 1.5 hours at 100° C.
A MED-4840/PLURONIC® F-127 membrane was manufactured using 8.4% PLURONIC® and 1.8% of a DCP cross-linking agent. This membrane was placed over a two-layer membrane having an enzyme layer and an electrode layer. The combined membrane layers were placed on a wholly implantable glucose sensor. The sensor was sterilized and implanted into a diabetic rat model.
A MED-4840/PLURONIC® F-127 membrane was manufactured using 20% PLURONIC® and a 20:1 ratio of DCP cross-linking agent per pluronic. Prior to curing, the material was drawn down and a cell-disruptive porous silicone membrane was placed on the uncured layer. After curing, the combined bioprotective/porous silicone membrane was placed over a four-layer membrane having a diffusion resistance layer, enzyme layer, interference layer, and electrode layer. The combined membrane layers were placed on a wholly implantable glucose sensor. The sensor was sterilized and implanted into a diabetic rat model.
A MED-4840/PLURONIC® F-127 membrane was manufactured using 8.4% PLURONIC® and 3.7% DCP. This membrane was placed over two-layer membrane having an electrode layer and an enzyme layer. The combined membrane layers were installed on a wholly implantable glucose sensor. The sensor was placed into a 2L bath filled with PBS (saline). The continuously stirred bath was brought to 37° C. and the sensor allowed to equilibrate for a minimum of 1 hour until the sensors reached a flat line continuous baseline signal. Acetaminophen was then added to the bath to a dilution of 3.8 mg/dl. The sensor was then allowed to equilibrate over 1 hour while measurements were continuously recorded from the sensor.
As a comparative example, a wholly implantable glucose sensor with a membrane not including a silicone/hydrophilic-hydrophobic polymer blend was tested. The membrane in this sensor included a three-layer membrane having an electrode layer, an enzyme layer, and a polyurethane diffusion resistance layer. A porous silicone cell disruptive layer was added on top. The sensor was placed into a 2L bath filled with PBS (saline). The continuously stirred bath was brought to 37° C. and the sensor allowed to equilibrate for a minimum of 1 hour until the sensors reached a flat line continuous baseline signal. Acetaminophen was then added to the bath to a dilution of 3.8 mg/dl. The sensor was then allowed to equilibrate over 1 hour while measurements were continuously recorded from the sensor.
Methods and devices that are suitable for use in conjunction with aspects of the preferred embodiments are disclosed in U.S. Publication No. US-2005-0176136-A1; U.S. Publication No. US-2005-0251083-A1; U.S. Publication No. US-2005-0143635-A1; U.S. Publication No. US-2005-0181012-A1; U.S. Publication No. US-2005-0177036-A1; U.S. Publication No. US-2005-0124873-A1; U.S. Publication No. US-2005-0051440-A1; U.S. Publication No. US-2005-0115832-A1; U.S. Publication No. US-2005-0245799-A1; U.S. Publication No. US-2005-0245795-A1; U.S. Publication No. US-2005-0242479-A1; U.S. Publication No. US-2005-0182451-A1; U.S. Publication No. US-2005-0056552-A1; U.S. Publication No. US-2005-0192557-A1; U.S. Publication No. US-2005-0154271-A1; U.S. Publication No. US-2004-0199059-A1; U.S. Publication No. US-2005-0054909-A1; U.S. Publication No. US-2005-0112169-A1; U.S. Publication No. US-2005-0051427-A1; U.S. Publication No. US-2003-0032874; U.S. Publication No. US-2005-0103625-A1; U.S. Publication No. US-2005-0203360-A1; U.S. Publication No. US-2005-0090607-A1; U.S. Publication No. US-2005-0187720-A1; U.S. Publication No. US-2005-0161346-A1; U.S. Publication No. US-2006-0015020-A1; U.S. Publication No. US-2005-0043598-A1; U.S. Publication No. US-2003-0217966-A1; U.S. Publication No. US-2005-0033132-A1; U.S. Publication No. US-2005-0031689-A1; U.S. Publication No. US-2004-0045879-A1; U.S. Publication No. US-2004-0186362-A1; U.S. Publication No. US-2005-0027463-A1; U.S. Publication No. US-2005-0027181-A1; U.S. Publication No. US-2005-0027180-A1; U.S. Publication No. US-2006-0020187-A1; U.S. Publication No. US-2006-0036142-A1; U.S. Publication No. US-2006-0020192-A1; U.S. Publication No. US-2006-0036143-A1; U.S. Publication No. US-2006-0036140-A1; U.S. Publication No. US-2006-0019327-A1; U.S. Publication No. US-2006-0020186-A1; U.S. Publication No. US-2006-0020189-A1; U.S. Publication No. US-2006-0036139-A1; U.S. Publication No. US-2006-0020191-A1; U.S. Publication No. US-2006-0020188-A1; U.S. Publication No. US-2006-0036141-A1; U.S. Publication No. US-2006-0020190-A1; U.S. Publication No. US-2006-0036145-A1; U.S. Publication No. US-2006-0036144-A1; and U.S. Publication No. US-2006-0016700A1.
Methods and devices that are suitable for use in conjunction with aspects of the preferred embodiments are disclosed in U.S. application Ser. No. 09/447,227 filed Nov. 22, 1999 and entitled “DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS”; U.S. application Ser. No. 11/280,672 filed Nov. 16, 2005, and entitled “TECHNIQUES TO IMPROVE POLYURETHANE MEMBRANES FOR IMPLANTABLE GLUCOSE SENSORS”; U.S. application Ser. No. 11/280,102 filed Nov. 16, 2005, and entitled “TECHNIQUES TO IMPROVE POLYURETHANE MEMBRANES FOR IMPLANTABLE GLUCOSE SENSORS”; U.S. application Ser. No. 11/201445 filed Aug. 10, 2005 and entitled “SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA”; U.S. application Ser. No. 11/335879 filed Jan. 18, 2006 and entitled “CELLULOSIC-BASED INTERFERENCE DOMAIN FOR AN ANALYTE SENSOR”; U.S. application Ser. No. 11/334876 filed Jan. 18, 2006 and entitled “TRANSCUTANEOUS ANALYTE SENSOR”; U.S. application Ser. No. 11/333837 filed Jan. 17, 2006 and entitled “LOW OXYGEN IN VIVO ANALYTE SENSOR”.
All references cited herein are incorporated herein by reference in their entireties. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.
The term “comprising” as used herein is synonymous with “including,” “containing,” or “characterized by,” and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps.
All numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that can vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.
The above description discloses several methods and materials of the present invention. This invention is susceptible to modifications in the methods and materials, as well as alterations in the fabrication methods and equipment. Such modifications will become apparent to those skilled in the art from a consideration of this disclosure or practice of the invention disclosed herein. Consequently, it is not intended that this invention be limited to the specific embodiments disclosed herein, but that it cover all modifications and alternatives coming within the true scope and spirit of the invention as embodied in the attached claims.